Submission to The Standing Committee on Health, Aged Care and Sport on Electronic Cigarettes and Vapourisers.

Professor Simon Chapman AO PhD
Professor Mike Daube AO
David Bareham MSc
Associate Professor Matthew Peters MD

6 July, 2017

Contact address

Prof Simon Chapman AO

School of Public Health, A27 University of Sydney, 2006 Australia

About the authors

Professor Simon Chapman AO PhD FASSA Hon FFPH (UK) is an Emeritus Professor in Public Health at the University of Sydney, from which he retired in February 2016. He has authored 515 articles, editorials and letters published in peer reviewed journals and 20 books and major reports. His work has been cited over 12,000 times. In 1997 he won the World Health Organisation's World No Tobacco Day Medal and in 2003 he was awarded the American Cancer Society's Luther Terry Award for outstanding individual leadership in tobacco control. In 2008 he won the NSW Premier's Cancer Researcher of the Year award and the Public Health Association of Australia's Sidney Sax medal. He was inaugural deputy editor (1992-1997) then editor (1998-2008) of the BMJ's specialist journal Tobacco Control. He is now its editor emeritus. In 2013, he was made Australian Skeptic of the Year and an Officer in the Order of Australia for his contributions to public health.
**Professor Mike Daube AO** has been Professor of Health Policy at Curtin University since 2005. Before this he was Director General of Health for Western Australia. His roles have included President of the Public Health Association of Australia, President of the Australian Council on Smoking and Health, Deputy Chair of the National Preventative Health Taskforce (and chair of the tobacco committee), Vice-Chair of the WHO FCTC Review Group, and chair, member and patron of many further government and non-government committees in Australia and elsewhere. He has worked on tobacco issues nationally and internationally for more than forty years, and has published widely on this and related issues. He is an Officer in the Order of Australia, and has received further awards from the World Health Organization, the American Cancer Society’s Luther Terry Distinguished Career Award, the Australian Medical Association, the National Heart Foundation of Australia, the Public Health Association of Australia, the Thoracic Society of Australia and New Zealand, Environmental Health Australia, the World Federation of Public Health Associations and many other organisations.

**David Bareham MSc** has been working as a Specialist Respiratory Physiotherapist at Lincolnshire Community Health Services UK NHS Trust for ten years. He currently has two peer reviewed articles related to electronic cigarettes, including one with *Lancet Respiratory Medicine*. He has another review article on e-cigarettes which has just been accepted for publication in the U.S. Last October, in collaboration with Professor Martin McKee and Professor Simon Capewell, he presented Expert Testimony to the English National Institute for Health and Care Excellence Public Health Advisory Committee on the Role of E-cigarettes in Smoking Cessation. His opinions here are his own, and not necessarily those of his employer.

**Associate Professor Matthew Peters MD FRACP FThorSoc** is a Respiratory Physician and Head of Respiratory Medicine at Concord Hospital. He has academic appointments at Macquarie University and Sydney University. Although a full-time clinician, he has authored over 100 peer-reviewed publications and he has supervised 10 successful PhD students. For more than a decade he was Chair of Action on Smoking and Health, Australia. In 2017 his work in preventing and improving the treatment and care of patients with lung cancer was acknowledged when he received a lifetime achievement award from Lung Foundation Australia.
Summary

The Therapeutic Goods Administration is in every sense Australia’s national “umpire” on claims about therapeutic product safety and efficacy. Its decisions over decades have given Australia one of the world’s best and most envied therapeutic regulatory systems. Those who have been working to have the TGA circumvented as this umpire are challenging its authority on the flimsiest of pretexts. They have refused to accept the TGA umpire’s decision, a course of action which brings them great discredit.

Given current knowledge of risk and uncertainty of benefit for ENDS, unregulated availability should not be an option. The purported benefits are small, uncertain and certainly unexceptional. However, evidence of harms are emerging.

As a core part of the case being put forward for the benefits of ENDS is based on a therapeutic claim (efficacy in smoking cessation), the TGA remains the appropriate regulator for nicotine-containing products. The TGA is also vastly experienced in assessing therapeutic product safety. For these two reasons ENDS must remain under TGA regulation.

To date, there is poor evidence of cessation superiority compared to best practice. Where an effect has been shown it has been small in magnitude. As concluded by the Cochrane Collaboration, the available data on ENDS’ efficacy in smoking cessation are low to very low in quality. The clearest conclusion is that there is no exceptional scientifically identified effect that would justify any exceptionalist departure from normal TGA regulatory processes. In addition, the available data apply to only a small number of device/delivery system/delivery parameter possibilities among the plethora available (and increasing in number). Lastly, it is important to consider that smoking cessation is the reason for use of ENDS in a declining minority of users (Ayers, 2017). Most users have no intent to quit smoking, but to only cut down in the false belief that reduced smoking is harm reducing. Because dual users (smoking plus ENDS) do not reduce their risk of harm, the majority of users therefore will not derive even any of the health benefits postulated.

The failure of governments in nearly every nation to regulate tobacco the product (advertising, packaging, misleading claims and smoke free areas are all strongly regulated) is not a sensible reason for removing ENDS from TGA regulation. To remove nicotine regulation from the TGA would be to learn nothing from the historic failure to regulate cigarettes. The argument being made by those urging this to happen is "cigarettes are an unregulated public health disaster and are freely available. Let’s now take the same unregulated route with ENDS."
Other than injuries caused by exploding ENDS, the harms that may arise from their long term use are unlikely to manifest in the short term. This was of course the history of emerging knowledge about the harms of smoking. Anyone proposing that cigarette smoking was apparently safe 10 years after mass use commenced would have been revealed to have been very badly wrong. ENDS advocates make such parallel claims today. These may turn out to be true or to be recklessly irresponsible - all the more reason to defer to the TGA.

The TGA’s regulatory assessment and scheduling powers will allow it to assess submissions for ENDS approval and to then calibrate scheduling that may be either strengthened or liberalised as evidence of harms and/or benefits emerge. Such flexibility is routine in the TGA and occurred (for example) with nicotine replacement therapy which was earlier a prescription only item and is now available in low doses over the counter.

Key questions for policy makers include:

- What is the net impact of the widespread use of ENDS?
- What might be the health effects of long term vaping?
- Does the proliferation in ENDS use tip more people permanently out of smoking than it holds in smoking because of widespread erroneous beliefs that cutting down cigarettes is harm reducing enough?
- Does it pull significant numbers of ex-smokers back into nicotine dependency?
- Does it see children and young people who may have never used any form of nicotine product start vaping or encouraged to think of vaping or smoking as normal and acceptable behaviour for them?

While some nations impose a ban on ENDS, the focus of this submission is on the case for regulating their content and availability through the established processes of the TGA.

**Note:** Throughout, we use the acronym ENDS (Electronic Nicotine Delivery Systems) to refer to electronic cigarettes and all other vapourising systems used to vapourise nicotine and all other materials that are inhaled by their users.

We have arranged the material in our submission sequentially to address the Committee’s Terms of Reference. Under each we have set out frequently asked questions often posed in the ENDS debate, and then addressed these. Appendices 1,2 and 4 are found at the end of this document. Appendix 3 is separately attached.

A study of smokers in 18 European nations published in *Preventive Medicine* [Fernandez et al, 2015] provides important data of direct relevance to the hardening hypothesis.
The most recognised way of measuring the “hardness” of smoking is the Heaviness of Smoking Index (HSI). This scores smokers out of a maximum of six, comprising a score of one to three for number of cigarettes smoked each day, and one to three on the time taken to lighting up the first cigarette of the day.

The European study, involving 5,136 smokers drawn from a total 18-country sample of more than 18,000 people, found that across the 18 nations, there was no statistically significant relationship between a nation’s smoking prevalence and the HSI.

If the hardening hypothesis was correct, nations with low smoking prevalence would have had higher HSI scores in the remaining smokers. They would have been smoking more cigarettes and lighting up earlier in the morning in nations with low smoking prevalence than in those with high. But they were not.

Similar findings have been reported for the United States. Data on smoking in 50 US states for 2006–2007 indicate that the mean number of cigarettes smoked daily, the percentage of cigarette smokers who smoke within 30 minutes of waking, and the percentage who smoke daily were all significantly lower in US states with low smoking prevalence (see http://www.bridgingthegapresearch.org/_asset/vgm11t/Giovino_2009_TobaccoChartbook.pdf). Again, this provides compelling evidence against the hardening hypothesis.

In Australia, a 2012 paper [Matthews, Hall & Gartner, 2010] examined three series of Australian surveys of smoking – the National Drug Strategy Household Survey (NDSHS), National Health Survey (NHS) and National Survey of Mental Health and Well-being (NSMHW) – that spanned seven to ten years.

The authors found that in two of the surveys (NDSHS and NHS), while smoking fell across the population, there was no change in the proportion of smokers who smoked less than daily, while in the NSMHW survey, that proportion increased from 6.9% in 1997 to 17.4% in 2007 (indicating a softening, not a hardening of smoking).

The authors concluded that the evidence presented:

“weak evidence that the population of Australian smokers hardened as smoking prevalence declined.”

Undeterred by this evidence, advocates for vaping centre their arguments around assumptions that there are many smokers who they claim are “unable” or “unwilling” to quit smoking. These are both very fluid and imprecise constructs.
Hundreds of millions have quit smoking

It is important to note that many hundreds of millions of smokers have quit smoking all over the world in the years before and since the evidence about the harms of smoking first began being publicised. Many very heavy smokers were among this population.

Most ex-smokers (between two-thirds and three-quarters) quit unassisted (i.e. without using any form of medication, nicotine replacement or getting professional assistance of any sort). [Chapman & McKenzie, 2010]. It is important to recall that nicotine replacement therapy (NRT) only became available in the early 1980s. Before that, a huge number of smokers stopped smoking permanently. [Smith & Chapman, 2014]. Those who stopped smoking without using NRT were not just light, non-addicted smokers but included many heavy and strongly addicted smokers.

In 1955, five years after Ernst Wynder and Evarts Graham’s historic study of smokers and lung cancer was published in JAMA (see http://www.epidemiology.ch/history/PDF%20bg/Wynder%20and%20Graham%201950%20tobacco%20smoking%20possible%20etologic.pdf) 7.7 million Americans (6.4% of the population) were former smokers. Ten years later, following widespread publicity surrounding the 1964 US Surgeon General’s Report, this had ballooned to 19.2 million (13.5%) ex-smokers.

By 1975, 32.6 million Americans (19.4%) had stopped smoking.

In 1978, the then director of the US Office in Smoking and Health noted in a National Institute of Drug Abuse Monograph, “In the past 15 years, 30 million smokers have quit the habit, almost all of them on their own.” (our emphasis) Many of these quitters had been very heavy smokers.

Today, quitting unaided (going “cold turkey”) remains the most common way that most ex-smokers have quit, despite more than 20 years of the availability and heavy promotion of nicotine-replacement therapy and other drugs and many other promoted methods of quitting both before and since. One should be very circumspect about voices trying to downplay this major and enduring phenomenon and promoting the view that stopping smoking requires pharmacological or professional help.

“Unable” to stop?

The “unable” to quit group are said to be those who want to stop smoking, but who have tried many times unsuccessfully and are now described by some as “unable” to stop smoking. It is certainly correct that some smokers find it very hard to stop smoking. But it
is equally the case that there are very many ex-smokers who after a succession of failed attempts to stop, then succeed. Indeed, many smokers who quit do so after a number of previous attempts. Such people therefore cannot be described as being “unable” to stop. They might better be described as being those who found it difficult to stop, to varying degrees.

Many quit attempts are clearly not serious attempts to stop, much in the same way that many attempts to get fit, lose weight, drink less and so on are also not serious attempts. Research has shown that many smokers who have had few thoughts about quitting make spontaneous quit attempts, and that such attempts are more successful than planned attempts [West & Sohal, 2006; Resnicow et al 2014]

Any roles that ENDS play in assisting some who find it difficult to quit are a far different proposition than that driving much vaping marketing which is to encourage as many smokers as possible to switch to ENDS. This would include many who may never have any serious difficulty in quitting.

Public policy on ENDS’ role in cessation needs to consider how best to make any ENDS products that have been approved for safety and quality accessible to smokers genuinely in need of this form of assistance, without risking the proliferation of these nicotine delivery devices to those who are likely to be able to quit anyway, to those who have no intention of quitting, and to non-smokers (especially children and young people).

Most smokers want to quit, and messaging from vaping interests that they should instead vape (and perhaps merely reduce their smoking) is a message that can seriously threaten the 50 year historical momentum for smokers to quit which has seen smoking rates in Australia fall almost continuously since 1980. This of course, would be an outcome that would be very welcomed by the tobacco industry, in which all major companies have bought into the ENDS industry. (see http://vaping360.com/the-battle-for-the-electronic-cigarette-market/)

In this respect, a core message of ENDS marketing is little different to those promoted over many years by tobacco companies during the many years of the low tar fraud, encapsulated by an infamous promotion for an earlier alleged harm reduced tobacco product, the US cigarette brand True (see below).
The “unwilling” to stop group

The “unwilling” group are often said to be those who enjoy smoking, or who have no interest or intention of stopping. However, ENDS advocates claim that many in this group have a strong interest in discontinuing smoking (overwhelmingly because of their awareness of the harms of smoking that have been so effectively communicated by tobacco control campaigns, pack warnings and doctor-patient advice) but want to maintain their nicotine addiction through vaping. They believe (or hope) that vaping is far less dangerous than continuing to smoke (see the next term of reference below) and that nicotine is virtually benign in the exposures received by smokers or vapers (also see term of reference #2 for comments on this point).

While some 90% of smokers regret that they ever started to smoke [Fong et al, 2004] some smokers claim that they “enjoy” smoking. A large part of the “enjoyment” that smokers get from smoking is the very palpable experience of relief that smokers get when the nicotine receptors in their brains are replenished with a dose of nicotine. When nicotine dependent smokers go without nicotine they can experience distressing symptoms - “cravings” - which are rapidly relieved by nicotine.
In this way, the "pleasure" of smoking is in large part the pleasure of avoiding the distress caused by the absence of nicotine in one's body. To refer to this as “pleasure” is like arguing that being beaten up every day is something you want to continue with, because it feels so good when the beating stops for a while. And clearly hundreds of millions of ex-smokers who experienced this “pleasure” decided that the risks it brought far outweighed the benefits of continuing.

What is the quality of the evidence to date about ENDS assisting smokers to quit smoking?

In assessing evidence about any intervention in smoking cessation, a variety of evidence can be considered.

**Randomised Controlled Trials**

Those who research the quality of evidence refer to high and low quality evidence. The highest quality evidence that can be considered in answering the question of whether vapourisers are useful in smoking cessation is the randomised controlled trial (RCT). This is where smokers wanting to quit smoking would be randomised into several different study groups. Typically, these would be where some would be allocated to use nicotine containing vapourisers; some given another form of smoking cessation intervention (such as NRT or varenicline); and others would be given a non-nicotine vapouriser (placebo).

At the time of writing (June 2017), there is only one recognised RCT that reasonably complies with these basic methodological characteristics [Bullen et al, 2013]. As the authors stated:

“657 people were randomised (289 to nicotine e-cigarettes, 295 to patches, and 73 to placebo e-cigarettes)…”. At 6 months, verified (biochemically confirmed) abstinence was 7.3% (21 of 289) with nicotine e-cigarettes, 5.8% (17 of 295) with patches, and 4.1% (three of 73) with placebo e-cigarettes (risk difference with nicotine e-cigarette vs patches 1.51 [95% CI -2.49 – 5.51]; for nicotine e-cigarettes vs placebo e-cigarettes 3.16 [95% CI -2.29 – 8.61]). Achievement of abstinence was substantially lower than we anticipated for the power calculation, thus we had insufficient statistical power to conclude superiority of nicotine e-cigarettes to patches or to placebo e-cigarettes.”

Other significant methodological concerns with this trial included that the delivery of nicotine e-cigarettes to participants was, unrealistically, via courier, whereas the patches group had to take a voucher to a chemist in order to obtain their nicotine replacement
therapy. Perhaps unsurprisingly, there was a high loss-to-follow-up noted in the patches group. It is entirely feasible, therefore, that the study overestimated the very “modest” effect size of nicotine e-cigarettes, and underestimated the effect size of well-managed nicotine replacement therapy.

Another RCT assessing the efficacy of ENDS for smoking cessation (Caponnetto et al, 2013) involved a study of smokers, though, in contrast to the aforementioned RCT study, not seeking to quit smoking. It involved only placebo comparison groups, and found no consistent differences in smoking cessation between nicotine e-cigarette and placebo e-cigarette.

In September 2016, the Cochrane Collaboration published an updated review and meta-analysis of this evidence, and the usefulness of electronic cigarettes in smoking cessation. It concluded:

“There is evidence from two trials that ECs help smokers to stop smoking in the long term compared with placebo ECs. However, the small number of trials, low event rates and wide confidence intervals around the estimates mean that our confidence in the result is rated ‘low’ by GRADE standards. The lack of difference between the effect of ECs compared with nicotine patches found in one trial is uncertain for similar reasons.” (Cochrane Collaboration Hartmann-Boyce et al, 2016)

However, in contrast to this analysis demonstrating, at best, a very weak positive association between e-cigarette use and smokers stopping smoking, another meta-analysis of the current RCT data [El Dib et al, 2017], identifying the aforementioned high loss-to-follow-up issue, highlighted that another entirely feasible interpretation (“plausible worse case sensitivity analysis”) is that e-cigarettes “fail to show a difference” in smoking cessation compared to placebo. As they point out:

“… the 95% CI of the relative risk crossed 1.0 and a plausible worse case sensitivity analysis to assess the risks of bias associated with missing participant data yielded results that were inconsistent with the primary complete case analysis.”

We understand that several RCTs are now under way. These should be important in increasing knowledge about ENDS’ efficacy in cessation.

**Cohort studies on cessation**

A lower form of evidence than RCTs is the longitudinal cohort study. This is where a group of smokers are followed for a long period to determine what proportions using different methods of trying to quit are not smoking at different times of follow-up. Because of the
very common phenomenon of relapse in smoking cessation, studies which report long follow-up data are more important than those reporting short-term findings,

The aforementioned Cochrane Review did not apply meta-analysis to cohort data on ENDS. However, the El Dib review did (n=8 studies), and in fact noted a potential suppression of chances in successful quitting when people use ENDS: “Cohort studies provide very low-certainty evidence suggesting a possible reduction in quit rates with use of ENDS compared with no use of ENDS” [El Dib, 2017].

**Cross-sectional studies**

Cross-sectional studies are a still lower form of evidence. These are where “snapshot” surveys of the community are undertaken and data obtained on the proportion of smokers who answer that they are no longer smoking.

Weaknesses in relying on this type of data include, fundamentally (as any epidemiology 1 student knows) that causality can never be claimed from cross sectional studies. Because data from participants in a cross-sectional (snapshot) studies are recorded only once, inference of temporal associations between ENDS use and smoking outcomes cannot be made. Only associations, not causation can be inferred from cross sectional studies.

An example of cross-sectional data from which inappropriate claims were made about e-cigarette cessation effects was a secondary analysis of the 2014 Eurobarometer survey data by Farsalinos and others (2016). Claims were made that vaping “caused 6.1m European smokers to quit smoking” (recently repeated in an article in the Sydney Morning Herald by Dr. Colin Mendelsohn - [http://www.smh.com.au/comment/ecigarettes-needed-to-get-more-adults-to-quit-smoking-20170625-gwybcb.html](http://www.smh.com.au/comment/ecigarettes-needed-to-get-more-adults-to-quit-smoking-20170625-gwybcb.html))

This causal factoid has been widely promoted through social media, but was demolished in the journal *Addiction* where it was published [Maziak & Taleb, 2016]. Among other criticisms, the critics in *Addiction* asked:

> “how many of those who claim that they have stopped with the aid of e-cigarettes would have stopped anyway, and how many of those who used an e-cigarette but failed to stop would have stopped had they used another method?”

They also noted that the questions asked in the survey would have allowed those who quit for only a short period to say they had “stopped”.

Longitudinal studies with a minimum of 12 months follow-up of randomly selected cohorts have shown sobering results, a long way from the hype of vaping having the equivalent
One such study reported that:

“Daily use of e-cigarettes while smoking appears to be associated with subsequent increases in rates of attempting to stop smoking and reducing smoking, but not with smoking cessation.” (our emphasis, Brose et al, 2015)

A companion paper [Hitchman et al, 2015] reported that daily tank system users were the only type of ENDS which showed a significant improvement in smoking cessation, although, the number of self-reporting vapers using these systems in that study was only 19.

Further, there are data which demonstrate that, for England, there are important differences between self-reported abstinence and biochemically verified abstinence. As West et al note:

“Self-reported cigarette and total tobacco smoking prevalence were assessed by means of the standard questions used . . . In subsamples, specimens were collected for analysis of cotinine (saliva, N = 1,613 in England . . .) providing an objective means of determining active smoking . . . Self-reported cigarette smoking prevalence using the standard methods underestimated true tobacco smoking prevalence by an estimated 2.8% in England . . . Cotinine concentrations in those misclassified as nonsmokers were indicative of high levels of smoke intake. Interpretation: Underestimation of smoking prevalence was significant in England . . .”. [West et al, 2007]

The same study identified no such discrepancy in U.S. data, and therefore, the validity of English ENDS survey data not utilising biochemical verification should arguably be viewed with this evidence in mind.

**Not approved as cessation devices in USA**

The current scientific evidence base does not, therefore, support recommending these devices as effective in smoking cessation. They are not approved as cessation aids by the US FDA [Brandon et al, 2015], nor by the US Preventive Services Task Force (USPSTF) which concluded “that the current evidence is insufficient to recommend electronic nicotine delivery systems (ENDS) for tobacco cessation in adults, including pregnant women” [USPSTF, 2015], an analysis with which we fully agree.

**What are the limitations of personal testimonies in establishing evidence?**

“the plural of anecdote is not evidence”.

Dr Tom Frieden, former Director of the US Centers for Disease Control and Prevention

The Committee will receive many testimonies from former smokers who will passionately explain that they were able to stop smoking by using ENDS. Many will argue that their experience self-evidently means that many others will, like them, also stop smoking after using an ENDS. Some of these will have been generated by tobacco companies such as Philip Morris, which have solicited such submissions to the inquiry. (see \http://www.abc.net.au/radio/melbourne/programs/mornings/big-tobacco-spamming-punters-to-submit-to-government-inquiry/8667096\)

Personal testimonies can also be found from ex-smokers on websites promoting smoking cessation strategies which are been shown under controlled research conditions to have very poor outcomes. These include acupuncture, “laser therapy” (see for example \http://www.imaginelaserworks.com/additional-services/stop-quit-smoking/\) and hypnosis, all of which have been assessed as being supported by very poor evidence of assisting smoking cessation. Those working in tobacco control are very familiar with a wide range of cessation approaches promoted by some quitters as the only or best approach because they worked for them. These range from astringents to herbal remedies to 5 Day Plans to clinics to books.

No one respectful of evidence gives any credibility to such personal testimony for cessation methods known from high quality reviews of evidence to be of poor efficacy. We should hold claims about the efficacy of ENDS in cessation to the same standards.

Those who quit smoking after using ENDS understandably attribute their smoking cessation to ENDS. Some want to spread their good news and encourage others to try to do what they have done. However, those who have tried and failed to quit using ENDS i.e. the substantial majority are far less likely to be as enthusiastic and evangelical. Positive personal testimonies represent flagrant self-selection bias about success and cannot be given any credibility when it comes to making generalisations about the success or otherwise of a cessation method.

**What proportion of long-term users of vapourisers still smoke? (”dual use”)**

The significant majority of adult smokers who try ENDS to quit smoking stop using them [Simonavicius et al, 2017; UK Office for National Statistics, 2016]. Most adults who use ENDS continue to smoke conventional cigarettes (“dual users”). In 2014 in the US, 93% of ENDS users continued to smoke cigarettes [Patel et al, 2016], 83% in France [Andler et al, 2016], and 60% in the UK [UK Office for National Statistics, 2016].
It is essential to highlight here that even ardent advocates of ENDS point out that:

“… concern(s) have been {partly} expressed that dual use” may encourage “smokers who could otherwise have quit elect for dual use instead, in the mistaken belief that this generates significant health gains” [our emphasis: Royal College of Physicians, 2016]

Professor Robert West (a leading figure in tobacco cessation research and director of the large Smoking in England national study told the BBC in February 2016, (http://www.bbc.co.uk/programmes/b070dq8h)

“[This widespread use of e-cigarettes] raises an interesting question for us: If they were this game changer, if they were going to be – have this massive effect on everyone switching to e-cigarettes and stopping smoking we might have expected to see a bigger effect than we have seen so far which has actually been relatively small” [our emphasis]

“We know that most people who use e-cigarettes are continuing to smoke and when you ask them they’ll tell you that they’re mostly doing that to try to cut down the amount they smoke. But we also know that if you look at how much they’re smoking it’s not really that much different from what they would have been doing if they weren’t using an e-cigarette. So I think as far as using an e-cigarette to reduce your harm while continuing to smoke is concerned there really isn’t good evidence that it has any benefit.” [our emphasis]

As background to this statement, West et al (2016) estimated that between 16 000 and 22 000 extra smokers may have quit per year in England because of ENDS use, above and beyond the number who would have quit in the absence of ENDS. At a population level this equates to a change in smoking rates of 0.044-0.061%. This figure can be placed into perspective when looking at the average annual fall in smoking prevalence that Australia (which has insignificant ENDS use) in the 25 years between 1991 (29.5%) and 2016 (14.9%). Australia has achieved an average annual fall 10 fold greater than the median estimate of 0.05% contribution calculated for ENDS by West et al. This ratio is similar if only the recent period 2010-2016 is examined. This small potential benefit would naturally have to be considered in conjunction with known ENDS harms.
West et al (2016) described their estimations thus:

"Evidence from RCTs and from surveys in England indicate that using an e-cigarette in a quit attempt increases the probability of success on average by approximately 50% compared with using no aid or LNP bought from a shop—similar to use of a licensed medicine with limited behavioural support but less than medication plus specialist behavioural support [6,7]."

The two references the authors used here were the Cochrane Collaboration review [Cochrane, 2016] (which noted that the evidence for smoking cessation with ENDS was low to very low) and a cross-sectional study [Brown et al, 2014] which have the weaknesses we described above. With the caveats that must apply to these sources, we would submit that no firm conclusions as to effect size can be credible, considering the fragility of these data.

The Committee should therefore be most circumspect in considering claims that ENDS use in the UK has caused a dramatic fall in smoking rates.

Very recent data from England show that about half of daily ENDS users are also smoking (Figure 1 below) and that the rate at which English smokers have tried to stop was the lowest in 2016 (30.9%) than it had been since 2007 (42.5%) when the study began (Figure 2 below). The decline in those attempting to quit is 11.6% in absolute terms and 27.3% in proportional terms. These are very disturbing data which would greatly please those in the tobacco industry.
Figure 1: About half of daily e-cigarette users in England are currently also smoking cigarettes.
These data raise important questions about whether ENDS may be holding many smokers in smoking even if they help some to quit. Moreover, new data concerningly suggest that non-daily vapers may actually increase their consumption of conventional cigarettes [Doran et al, 2017]. Further, it has been suggested that one of the key reasons for US cigarette consumption being higher higher in 2015 than in 2014 (the first time cigarette consumption increased since 1973) [Wang T et al. 2017], was because of continued dual use. Recent qualitative data, where dual users are asked about their continued smoking and vaping behaviours, suggests that dual users may find it harder to quit, as they do not actually view themselves as smokers [Vandrevala et al, 2017].

Key questions for public health therefore include: what is the net impact of the widespread use of ENDS? Does the proliferation in ENDS use tip more people permanently out of smoking than it holds in smoking? Does it pull significant numbers of ex-smokers back into nicotine dependency? Does it see children who may have never used any form of nicotine
product start vaping or encouraged to think of vaping or smoking as normal and acceptable behaviour for them? What might be the health effects of long term vaping?

Marketing

Interest groups promoting ENDS understandably wish to be allowed to promote their products to as wide an audience as possible. These groups are generally cognisant of the need to at least appear to be acting responsibly, by claiming they do not want children to use ENDS. However, the reality with ENDS at the retail level suggests the opposite. Results of a recent UK Chartered Trading Standards Institute investigation [CTSI, August 2016] identified that approximately 40% (246/634) of retailers illegally sold nicotine e-cigarettes and vaping liquids to children and young people, with 50% (68/137) specialist vaping shops “flouting” laws regarding the selling ENDS and nicotine e-liquids to children.

Another example of this was exposed recently by the UK Royal Society for Public Health [RSPH, 2017], which undertook an undercover investigation of 100 of the UK’s 1700 independent vape shops. Nearly nine in 10 stores (87%) were either knowingly, or unwittingly, selling ENDS to people who have never smoked or vaped. As was highlighted by the RSPH:

“Almost half (45%) of stores did not check whether new customers were current or former smokers.”

“Three quarters (76%) of those that did check continued to encourage the customer to start vaping, even once they knew they were a non-smoker.”

“This is in direct violation of the Independent British Vape Trade Association (IBVTA) code of conduct which states: “Vape products are for current or former smokers and existing users of vaping devices, therefore never knowingly sell to anyone who is not a current of former smoker, or a current vaper.”

(http://www.ibvta.org.uk/join-us/code-of-conduct)

“The code of conduct exists to ensure e-cigarettes are perceived as an effective aid for quitting smoking, rather than as a lifestyle product” [RSPH, 2017].

Allegations of “irresponsible” marketing tactics utilised by elements of the ENDS industry were recently made by Dr K Farsalinos, a vociferous advocate for the potential of ENDS to help adult smokers quit, who stated:
“I wonder if there is anyone who thinks that the use of cartoons and funny graphics... is not going to be perceived as appealing, and an attempt to actively promote the products, to youth... this is absolutely unacceptable and a clear indication of irresponsible behaviour...” (Farsalinos, 2017)

Industry claims of being public health allies are obviously nothing but cynical public relations gestures because, like all industries, the future of ENDS commerce depends on new users. With ENDS, this means non-users of ENDS taking them up and becoming addicted to nicotine via ENDS. Smokers are an obvious target, but children are another which cannot be airbrushed out of public policy considerations (see Term of Reference #5 below).

The same tobacco companies which are now heavily investing in ENDS have always strenuously publicly denied that they do not want children to smoke.

Voluminous evidence from their own internal documents reveals that such statements were duplicitous public relations statements [Assunta & Chapman, 2004; Knight & Chapman, 2004]. If the ENDS industry is to survive, and flourish, it will need to attract new users: adult smokers, adult non-smokers and youth, which it appears to be attempting to do. It is manifestly in the interests of tobacco companies and any others involved in the e-cigarette industry that children and young people should view their products favourably and be encouraged to use them. Any denials on this issue carry as much credibility as tobacco industry denials over the decades.

The figure below shows an example of the sort of packaging and promotional appeals that have been seen in England recently. This link shows examples of ENDS promotions with major appeal to children in the USA

http://www.tobaccofreekids.org/tobacco_unfiltered/post/2015_06_17_ecig
As the University of Bath Research team point out “E-cigarettes are being marketed in a way which emulates very successful tobacco advertising asserting an independent identity and a lifestyle choice, aligning oneself with celebrities, fashionable and youthful places and activities.”

The current bill before the Senate presented by Senators Leyonhjelm and Roberts (Vaporised Nicotine Products Bill 2017) seeks to allow the advertising of ENDS through
changes to the Tobacco Advertising Prohibition Act 1992. There is no known form of advertising which can only be seen by adults but not by children. Should this Bill succeed, ENDS marketers would be effectively free to promote their products, brand names and corporate identities to the entire community, including (non-smokers as well as smokers, children and young people. We would doubtless witness the same farcical and totally ineffectual “safeguards” against this as we witnessed with assurances about non-appealing advertising and children with tobacco advertising in the 1980s and even earlier. It is indeed fifty years since the late Senator Robert Kennedy said in 1967, 

“If we were starting afresh, I would say the first line of action would be industry self-regulation of advertising. But we have witnessed a charade of purportedly self-regulation for some years. The codes of self-regulation have been largely ineffective, and I see little hope for change. The industry we seek to regulate is powerful and resourceful. Each new effort to regulate will bring new ways to evade”.

Giving the tobacco industry or any others carte blanche to advertise e-cigarettes would be a catastrophic error - yet another demonstration of the need to respect the processes of the TGA.

Below are photographs taken in NSW of ENDS products being sold alongside confectionery at eye-level, where young children would easily see them. Tobacco products are required to be stored out-of-sight in all Australian states and territories. We believe the same regulations should apply to ENDS products.
Term of Reference #2. The health impacts of the use of e-cigarettes and personal vaporisers

Unlike inhaling tobacco smoke from combusted tobacco products, inhaling vapour does not involve inhaling the smoke arising from combusted tobacco. That smoke contains carbon monoxide, tar, many carcinogens and co-carcinogens, toxicants and irritants. ENDS do not ignite the contents of the liquids which are vapourised. They instead heat them, and so there is no carbon monoxide or “tar”.

From this, it has been argued that inhaling vapour will be eventually acknowledged to be of far less risk to health than smoking. However, many ENDS advocates are adamant that we know this to be true already, barely a decade after ENDS use began to be used widely in some countries.

They argue that there is no need to wait any longer before adopting policy based on assumptions that ENDS are all but benign, and accordingly ENDS should be treated as such.

They argue that smoking now kills 7 million people a year and will kill an estimated 1 billion during this century and that widespread use of ENDS will see such figures dramatically reduced. This would be self-evidently a wonderful thing if it their predictions were to be later shown to be correct. But as we will argue, the evidence that we have confidence that we currently have to inform these predictions is very scant. There is also overwhelming evidence that tobacco companies selling and promoting ENDS are indeed doing all they can to continue to aggressively promote cigarettes - and hence the deaths they cause - in both developing and developed countries.

Tobacco control has had a long history of wild, unbridled and commercially driven enthusiasms for purported reduced harm products (filters, asbestos filters, reduced carcinogen cigarettes, “low” tar, “lights”, tobacco substitutes, etc). None of these were subsequently demonstrated to reduce harm is those who used them. [Parascandola, 2011]. It does not follow from this that ENDS will similarly be found to fail as harm reduction devices, but the long history of failure and the consequences of again promoting false hopes must give all responsible authorities strong pause for consideration.

This submission is not a formal, systematic review of the research literature on ENDS. However, our concern is to give some perspective to the obvious campaign by ENDS...
advocates to present an entirely sanitized view of what is known about the health risks of ENDS use.

There is a rapidly growing toxicological research literature on the health effects of ENDS.

Appendix 1 below shows an indicative recent selection of such research. No one reading this research who had an open mind as to whether ENDS might be seriously harmful could form the view that they were free from serious concerns and should be sold as freely as grocery items, let alone widely promoted.

With respect, parliamentary committees are not in a position to assess the scientific quality of specialised toxicological research such as that we have highlighted in this submission and in Appendices 1 and 2. In Australia, that is very obviously and properly the role of expert bodies like the TGA and the NHMRC which can convene and commission independent scientific expertise to advise governments.

Both have already done this with ENDS.

Is it too soon to know whether vapourisers are really far less dangerous than cigarettes?

It has been claimed, utterly bizarrely, by some that:

“The paucity of evidence for serious harm to users of e-cigarettes over the years since they were first marketed in 2006, with millions purchased, in itself is evidence” that they do not cause such serious harm (Nutt et al, 2016).

The main diseases caused by smoking (cancers, respiratory and cardiovascular) are known as chronic diseases. While there can be some people who manifest smoking-caused health problems early, clinical signs of diseases like lung and heart diseases and cancers typically begin to show up in larger numbers several decades later. The harms of smoking do not manifest quickly in the ways that those resulting from exposure to infectious or acutely toxic agents do. The aforementioned claim by Nutt et al is, therefore, at odds with what is well established with conventional cigarettes.

Smoking skyrocketed when cheap, affordable cigarettes first appeared early in the twentieth century following the invention of mechanised cigarette rolling machines. Over the next 20 years, lung cancer remained an uncommon, even rare disease.
The US surgeon Alton Oschner, recalling attendance at his first lung cancer autopsy in 1919, was told he “might never see another such case as long as we lived”. He saw no further cases until 1936 -- 17 years later -- and then saw another nine cases in six months. Today lung cancer is (by far) the world’s leading cause of cancer death.

The incidence of lung cancer rose rapidly in the decades 1930-1980 but it was not until 1950 that definitive evidence was published in the USA and the UK that long-term smoking caused lung cancer, by far the most common form of fatal cancer today. Knowledge about smoking’s causal role in other diseases followed.

If any scientist had declared in 1920 that cigarette smoking was all but harmless, history would have judged their call as dangerously incorrect. But this is the reckless call that many ENDS advocates are making today, after just 10 years.

**What is the provenance of the claim the e-cigarettes are “95% safer” than cigarettes?**

This number was produced by a hand-picked group of 12 [Nutt D et al, 2014] who were asked to rank the health risks of 12 nicotine delivery products, including cigarettes. Several of the group had no research track record or expertise in tobacco control and some had histories of financial connections with manufacturers of ENDS and tobacco companies [Gornall, 2015]: a network diagram from the British Medical Journal ([http://www.bmj.com/content/351/bmj.h5826/infographic](http://www.bmj.com/content/351/bmj.h5826/infographic)) shows these interconnections between some of the authors. The authors stated that “There was no formal criterion for the recruitment of the experts although care was taken to have raters from many different disciplines.”

However, there were no toxicologists, cancer or cardiovascular specialists among the authors. The “95%” number was uncritically repeated in a Public Health England (2015) review and report, which amazingly even described e-cigarettes as “around 95% safer [not less dangerous] than smoking” (our emphasis). Incredulous toxicologists have since pointed out: “there is no evidence for the 95% estimate” [their emphasis, Combes & Balls, 2015]

Even the pro-ENDS activist Carl Phillips, who has a long history of support from tobacco manufacturers (see [http://www.tobaccotactics.org/index.php/Carl_V_Phillips](http://www.tobaccotactics.org/index.php/Carl_V_Phillips)), summed up this study as follows:

“This specific point estimate (synonymous with “5% as bad for you as smoking”) has rapidly evolved into “fact” (in the political sense of that term). It is repeated in a large fraction of popular press reports and widely used in arguments, snipes, and broadsides from vaping advocates. *It seems to have emerged from nowhere* when the
Public Health England report asserted the figure. That traced to what was actually a huge misinterpretation of what was only a made-up number, from one junk-science journal article.” (our emphasis) [https://antithrlies.com/2016/05/25/saying-e-cigarettes-are-95-less-harmful-is-a-very-bad-idea-part-143-of-10000/](https://antithrlies.com/2016/05/25/saying-e-cigarettes-are-95-less-harmful-is-a-very-bad-idea-part-143-of-10000/)

Moreover, several UK organisations which have cited this paper as being central to their perspectives (e.g. Public Health England; Royal College of Physicians; NHS UK) appear not to have noticed that the group of twelve authors themselves stated that:

“A limitation of this study is the lack of hard evidence for the harms of most products on most of the criteria.”

So, a group of 12 people estimated that ENDS were 95% less dangerous than cigarettes, despite acknowledging themselves that they had a “lack of hard evidence of most products on most of the criteria” for their guess. This is hardly surprising, as this risk estimation exercise was carried out in the summer of 2013, just a few years after ENDS devices became readily available to consumers.

Bizarrely, the authors of the “study” subsequently attempted to respond [Nutt et al, 2016] to extensive criticism of it [Lancet, 2015] by attempting to counter the correct observation that their study suffered from, among other things, a lack of hard evidence. As noted above, they had, themselves, explicitly stated in the original article that this was, indeed, the case.

**Didn't both the Public Health England and the Royal College of Physicians reports on e-cigarettes endorse the “95% safer” figure?**

Yes they did, however, neither of these two groups provided any data, calculations or formal risk assessment to substantiate the production of the “95%” figure, nor indeed, any possible figure. They would have appeared to have just repeated the same, identical opinion-led “justifications” originally published by the Nutt et al group.

**So what is the true risk of e-cigarettes compared with cigarettes?**

We have often been asked “well, if you question the risk as being 95% less dangerous, what is your estimate?” Those asking this question appear to not understand that no estimate can be made currently that has any acceptable toxicological degree of accuracy. This is the opinion of expert toxicologists, who have noted:
“... Public Health England and the Royal College of Physicians in the UK, largely relied on expert opinion and where evidence was considered it largely focused on studies of vaping aerosol and e-liquid composition with relatively few biomarker studies...”[Wilson et al, 2016]

Their subsequent analysis of the few recent relevant biomarker studies available at the time of their review revealed a:

“... very diverse range of results... but all suggest lower levels of risk for vapers compared to tobacco smokers”. However, “preliminary evidence ... suggests that the effect of vaping on four ... inflammatory markers of likely relevance to cardiovascular disease (CVD) and respiratory disease may be at least half that of tobacco smoking” and “The results for cancer-related toxicants were variable, from 0% to 23% of the levels observed for tobacco smokers, with most studies reporting between 14% and 23% – a substantial level of exposure” [Wilson et al, 2016, our emphasis].

Because of the relatively few years in which people have vaped, it is not currently scientifically possible to provide a credible single figure estimate of risk. The World Health Organisation confirmed this when they stated:

“The magnitude of these risks is likely to be smaller than from tobacco smoke although there is not enough research to quantify the relative risk of ENDS/ENNDS over combustible products. Therefore, no specific figure about how much “safer” the use of these products is compared to smoking can be given any scientific credibility at this time” [WHO, 2016]

Two toxicologists put it rather more bluntly, that to label ENDS as “low risk” products is:

“in the light of current knowledge, a reckless and irresponsible suggestion”... such a view “ignores the possibilities that users might be repeatedly exposed to hitherto undetected contaminants and by-products, as well as to carcinogenic chemicals, or their precursors (which have been detected in solvent extracts and vapours, and which are derived from tobacco during solvent extraction or generated during solvent heating), that can have effects at very low dose levels, following repeat exposures, which can occur without clear threshold doses, thus necessitating zero-dose extrapolation.” (their emphasis, Combes and Balls, 2015).

As key co-authors of the 2016 UK RCP “Nicotine without smoke” review stated at the same time that the RCP review was published, ENDS are highly unlikely to be harmless:
“long term use is likely to be associated with long term sequelae, including an increased risk of chronic obstructive pulmonary disease, lung cancer, possibly cardiovascular disease, and some other long term conditions associated with smoking” [Britton et al, 2016; WHO, 2016] i.e. sequelae associated with the well-documented spectrum of harm caused by smoking conventional cigarettes.

Vaping advocates urge smokers to switch to ENDS. Those who fully switch are likely to experience reduced risk of premature death from smoking caused diseases, but the magnitude of that risk remains entirely speculative, in the absence of any large longitudinal population studies.

**How often do vapers inhale vapour?**

In 2014, the US tobacco company Lorillard posted on a website advising parents about how they could talk to their children about vaping, claiming, misleadingly and irresponsibly, that:

"The 'smoke' you see coming out of e-cigarettes isn't smoke -- it's WATER VAPOR."

([http://www.tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/What%20you%20need%20to%20know%20about%20e-cigarettes%20%E2%80%93%20Infographic%20%20Parents%20Answers_may31-2014.pdf](http://www.tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/What%20you%20need%20to%20know%20about%20e-cigarettes%20%E2%80%93%20Infographic%20%20Parents%20Answers_may31-2014.pdf) and


Vapers average about 200 inhalations a day, with a 2016 study [Martin et al, 2016] finding a range of 6 to 611 puffs, an average 73,050 deep lung bastings a year, up to 223,168. Like cigarette smoke, vape mist normally contains, as well as nicotine, normally, a cocktail of toxic contaminants and by-products, for example, proinflammatory fine, ultra-fine and nano-particles [Fouco et al, 2013], potentially harmful and carcinogenic metals and silicate [Williams et al, 2013; Hess et al, 2017], toxic and carcinogenic aldehydes [Kosmider et al, 2014], and potentially cytotoxic flavourings [Farsalinos et al, 2015]. It is anything but just like “inhaling steam in a shower”, as some on vaping blogs have irresponsibly tried to describe it.
Lung Health

The primary target or site of inhaled ENDS vapour is the lung. The lungs have a combined surface area the size of a tennis court and are hugely exposed to vapourised products. For organic compounds, other chemicals and heavy metals, in vapour that can be absorbed into the lung circulation, there is a broad access avenue. Normally, the lungs have a critical surface fluid lining that is vanishingly thin so that the volume of this fluid is less than 5mls. At the conclusion of a vaping session, it has been estimated that half of the lining fluid composition is derived from the vaping inhaler. [Manigrasso, M., et al 2015]

This is critically different from an asthma spray. 99% of the propellant of an asthma spray is exhaled unaltered in gaseous form with the active drug in powder form being left behind (Leach, 2005).

Further, for the majority of ENDS users who are also current smokers, the altered lung lining fluid may actually increase exposures to toxins within cigarette smoke. Normal lining fluid is little more than salty water and fat-based toxins from smoke cannot dissolve in it. [Fröhlich, 2017]. In contrast, by its very nature, ENDS vapour is an excellent solvent. Changing the properties and constituents of lung lining fluid may, for example, change the absorption and effect of common treatments for asthma or alter in a very deleterious fashion cigarette smoke particle transit in the majority of ENDS users who continue to smoke.

That this change in the lung liquid interface is a real, and not just a theoretical, risk is supported by data from aviation safety training that shows changes in the basic properties of tear fluid in the eyes from propylene glycol [included in almost all ENDS] exposure in aviation safety training exercise.

A highly detailed review of the lung toxicity of ENDS has recently been published in the American Journal of Physiology [Chun et al, 2017]. This was funded by the US FDA and the National Cancer Institute. The review concludes:

“In summary, there is a rapidly growing body of evidence derived from in vitro, animal, and human studies that e-cigarette use may have significant pulmonary toxicity.” (our emphasis)
Specific harms that the review addresses include:

A. Harms in adolescent ENDS users

In a study of 45,000 adolescents in Hong Kong, use of ENDS in the preceding 30 days doubled the risk of cough and phlegm in both ever smokers and never smokers [Wang et al 2016]. In a separate study of 40,000 adolescents in South Korea, ENDS use more than doubled the risk of asthma being diagnosed and more than trebled the frequency of school absence related to asthma [Cho & Paik 2016]. These harms are real, immediate and a cause for concern about protecting children from ENDS whether containing nicotine or otherwise.

B. Harms of flavourants and other vehicle compounds.

ENDS contain many flavourants that are approved for oral ingestion but not for inhalation. Further, the superheated environment in ENDS alters these chemicals to definite toxins and higher levels of toxins, equal to or greater than those seen in cigarette smoking. This can be seen when variable power devices are set to their highest setting. In particular the carcinogen formaldehyde and other aldehydes may be present in higher concentrations (Khlystov and Samburova, 2016).

C. Harms of heavy metal exposures

The heating coil for ENDS can easily decay or flake and cause toxic heavy metals to be included in solution or as a particle in the vaped aerosol. These include nickel, chromium and aluminium. All are carcinogens and all are better not inhaled. Silicates that are also carcinogenic may also be formed. [Williams et al 2013]

What do we know about the health consequences of inhaling nicotine many thousands of times a year?

ENDS advocates have sought to trivialise the health risks of nicotine, regularly sheltering behind the slogan: “People smoke for the nicotine but die from the tar” [Russell, M. 1991]

The inhalation of nicotine, however, may be anything but benign. The International Agency for Research on Cancer [IARC, 2014] recently noted that they had not previously evaluated electronic cigarettes and nicotine. They describe current evidence, and note that “recent evidence has indicated the potential for nicotine to cause DNA damage” and “In addition, exposure to nicotine has been shown to inhibit apoptosis, and stimulate cell proliferation and angiogenesis . . .”. Subsequently, due to their rapid uptake as consumer products in
many countries, the IARC declared that an evaluation of electronic cigarettes and nicotine is a “High Priority”.

Appendix 2 lists recent research reports about the possible role of nicotine as a cancer promoter. This growing area of research underscores why it remains entirely appropriate that nicotine should remain within the regulatory oversight of the TGA in Australia.

*There is no ENDS device that is a purely nicotine delivery system.* Most ENDS deliver nicotine, which has its own toxicity as well as, clearly, the well documented effect of psychophysiological addiction. But they also deliver a variety of chemical vehicles/solvents, flavours etc that are separately and perhaps cumulatively toxic, and none of which are approved for inhalation in the form that they are included in solutions or in any chemically altered form that might emerge after superheating. As has been articulated by toxicologists:

“… users might be repeatedly exposed to hitherto undetected contaminants and by-products, as well as to carcinogenic chemicals, or their precursors (which have been detected in solvent extracts and vapours, and which are derived from tobacco during solvent extraction or generated during solvent heating), that can have effects at very low dose levels, following repeat exposures, which can occur without clear threshold doses, thus necessitating zero-dose extrapolation” (Combes and Balls, 2015)

**Many vapers reduce how much they smoke. Isn’t reducing smoking obviously harm reducing?**

Recent studies with small groups of subjects [Goniewicz et al, 2017; Shahab et al, 2017] indicate that smokers who fully switch from cigarettes to ENDS reduce their exposure to various carcinogens and toxicants. They highlight, however, that “e-cigarettes are likely to be beneficial only if complete cessation of combustible cigarette smoking is achieved” [Shahab et al, 2017]. As we have discussed, large proportions of ENDS users are dual users and continue to smoke, so are highly unlikely to be reducing harm.

While there is strong evidence for a causal association between early uptake, amount smoked and duration (pack years) of smoking, the evidence on “reverse engineering” harm by continuing to smoke while cutting back is far from strong.

A Norwegian cohort of 51,210 people followed from the 1970s until 2003 found “no evidence that smokers who cut down their daily cigarette consumption by >50% reduce their risk of premature death significantly” [Tverdal & Bjartveit K. 2006]. A Scottish study [Hart et al, 2013] of two smaller cohorts followed from the 1970s to 2010 found no
evidence of reduced mortality in reducers, but clear evidence in quitters and concluded “that reducing cigarette consumption should not be promoted as a means of reducing mortality.” The largest study, from Korea [Sung et al, 2008] and involving 479,156 men followed for 11 years, found no association between smoking reduction and all cancer risk but a significant decrease in risk of lung cancer, with the size of risk reduction “disproportionately smaller than expected”.

A 2007 systematic review of the evidence on the health impact of reduction which included none of the above important studies, noted that most studies examined reductions in smoking of more than 50%. It found:

“A substantial reduction in smoking seems to have a small health benefit, but more studies are needed to determine the long-term effects of smoking reduction” [Pisinger and Godtfredsen, 2007].

The apparently commonsense argument that it must be self-evidently true that continuing to smoke, but only smoking less than before, is harm reducing is therefore very poorly supported by research evidence.

**What do we know about inflammation associated with vaping?**

We have emphasised that it is far too soon to know at the population level whether widespread vaping will cause significant health problems, or health gains. We have further noted that vapers who stop smoking and fully switch to ENDS are exposed to much lower levels of many toxic and carcinogenic substances [Goniewicz et al, 2017; Shahab et al, 2017].

However, serious health effects can be observed when exposure to doses of such substances are very low [Combes & Balls, 2015]. For example, there is evidence that the dose-response curve for the potent lung carcinogen NNK, as identified in e-cigarette aerosol [Goniewicz et al, 2013] is highly nonlinear, has no clear threshold, with substantial increases in occurrence of lung cancer at very low doses [Hengstler et al, 2003, Figure 9, cited in Combes & Balls, 2015].

Recent independent comprehensive reviews of the current literature on health risks are available, and highlight both potential cardiovascular risks [Bhatnagar et al, 2016; Schweitzer et al, 2017]) and respiratory risks [Chun et al, 2017]. For example, Glycerol, one of the two solvent agents utilised in delivering nicotine and flavourants in e-cigarette fluid, when heated to even very low temperatures (relative to combustion temperatures), has been known for at least 90 years to thermally decompose and form, among other
chemicals, the highly toxic aldehyde acrolein [Lawrie, 1928]. The smell of burnt fat, when cooking oil is heated, is caused by glycerol in the burning fat breaking down into acrolein; there is growing evidence that chronic inhalation of such cooking fumes is related to lung disease [Juntarawijit C & Juntarawijit Y, 2017]. As the aforementioned reviews show, low dose acrolein has the potential to cause both respiratory and cardiovascular disease [Chun et al, 2017; Bhatnagar et al, 2016; Schweitzer et al, 2017]. Inhaled low dose acrolein has been strongly associated with causing chronic pulmonary inflammation i.e. COPD, a reduction of host respiratory defenses, neutrophil inflammation, mucus hypersecretion and protease mediated lung tissue damage [Moretto et al, 2012]. Moreover, “prolonged exposure to even low-dose . . . acrolein results in nonspecific inflammatory cardiac lesions” [Bhatnagar et al, 2016].

On the crucial issue of aldehyde exposure, a highly critical review of a key paper postulating that users of ENDS do not inhale significant levels of acrolein and other toxic aldehydes (e.g. formaldehyde, acetaldehyde) [Shihadeh et al, 2015] highlighted substantial problems with the paper. Shihadeh et al (scientists active in the field of electronic cigarettes, including exposures to aldehydes), highlighted that the criteria commonly considered during peer review (i.e. that “the method be described sufficiently so as to allow replication, results and data analytical techniques are presented thoroughly, and conclusions are based on the results presented”) were “not met” by Farsalinos et al in 2015. [Farsalinos et al Addiction, 2015]

However, the Farsalinos et al (2015) study was uncritically cited by Public Health England 2015 as evidence that that puffs of ENDS aerosol, relatively rich in toxic aldehydes, are “instantly detected [by vapers] due to a distinctive harsh and acrid taste. This poses no danger to either experienced or novice vapers, because [such] dry puffs are aversive and are avoided rather than inhaled.”

This presumption was based on only this one study of just seven vapers using unflavoured liquid. This flavouring issue is important, as some flavours are already known to potentially mask the harsh, acrid tastes of cigarettes, and therefore, potentially, ENDS [Alpert et al, 2015]. The original Farsalinos et al study itself recommended further studies to better understand interindividual differences in tasting perception. Longitudinal studies would further be needed in order to establish potential changes in perception: it has been correctly noted that some smokers, over time, learn to “overcome” and inhale puffs of cigarette smoke, rich in aldehydes [Rowell and Tarran, 2015]. These issues highlight the importance of: sticking to the scientific method; appropriate peer review; and of replication and expansion of results, prior to influential public health organisations making, in effect, unsubstantiated generalisations from one small study.
Highly reactive free radical production, also implicated in the causation of the irreversible inflammatory lung disease COPD from cigarette smoking, has also been identified in ENDS aerosol [Goel, 2015]. The volumes of highly reactive free radicals collected were, perhaps predictably, much less than those in found in cigarette smoke, presumably related to the absence of combustion in ENDS aerosol production. However, as the authors point out:

“Since the overall levels of radicals are significantly lower than those observed in conventional cigarette smoke, it might be expected that the degree of damage might be less, but this depends on the identity and reactivity of the specific radicals produced” [Goel et al, 2015]

Research already carried out in human subjects (Martin et al, 2016) indicates that ENDS suppress genes involved in the immunity and inflammatory responses of users: the authors signal the necessity for further research into the respiratory consequences of vaping.

A very recent review of the potential cardiovascular risks of vaping concluded that:

“The majority of studies found some evidence of a significant risk effect for e-cigarettes, although the evidence was not totally consistent within and between studies. Suggestive evidence also implicates a possible effect of e-cigarettes on inflammation processes. Levels of risk indicators for e-cigarettes were sometimes lower than those found for cigarettes but several studies showed comparable effects” [Schweitzer et al, 2017].

As noted above, ENDS work by creating an aerosol of ultrafine particles that carry nicotine deep into the lungs of users, and thereby into the bloodstream to the heart, and then to the brain. These particles are as small as – and sometimes smaller – than those in conventional cigarettes [Fuoco et al, 2014]. Importantly, these ultrafine particles are biologically active, and can trigger inflammatory processes that are directly implicated in causing cardiovascular disease, and acute cardiovascular events [Pope C et al, 2009]. The dose-response effect for exposure to these particles, similar to the above example of the potent lung carcinogen NNK, is nonlinear, with substantial increases in cardiovascular risk with even low levels of exposure to ultrafine particles [Pope et al, 2009]. There is some evidence, already emerging, of a potential link between ENDS use and increased risk of heart attacks [Temesgen et al, 2017. See link to full discussion of this new data in the Reference List].

ENDS expose users who fully switch to them to reduced levels of carcinogens, which may likely reduce their risk of cancer. However, it should be noted here that most of the premature, preventable deaths associated with smoking tobacco are related to cardiovascular and non-cancer respiratory disease, and not cancer [U.S. Department of
Health and Human Services, 2014], and that current interpretation implicates significant cardiovascular and non-cancer respiratory health risks.

**Is it safe to inhale vapourised propylene glycol?**

Propylene glycol (PG), like glycerol, is a chemical used in vaping liquid in which the nicotine and flavour chemicals are vapourised and transported into the lungs. There are some very old data on the effects of inhaled PG in animals [Robertson & Loosli, 1947], which are regularly cited in the literature relating to potential positive effects [e.g. Farsalinos and Polosa, 2014]. However, Dow Chemical, which manufactures PG, says unambiguously, reflecting data from human subjects (Weislander et al, 2001), that:

“... breathing spray mists of these materials should be avoided. In general, Dow does not support or recommend the use of Dow’s glycols in applications where breathing or human eye contact with the spray mists of these materials is likely...”

(DOW, 2003)

Weislander et al highlighted that:

“Short exposure to PG mist from artificial smoke generators may cause acute ocular and upper airway irritation in non-asthmatic subjects. A few may also react with cough and slight airway obstruction.”

It has been incorrectly claimed by some that PG is a solvent utilised in the delivery of inhaled nebulised medications for asthma sufferers, and that, therefore, “it must be safe”. No standard asthma inhaler in Australia contains propylene glycol. However, there is evidence that it is in fact the case that PG is used in this therapeutic fashion, although, it is “a commonly used drug solubilizer in topical, oral, and a very limited number of injectable medications” (https://www.drugs.com/inactive/propylene-glycol-270.html).

This view has been articulated even by active advocates of vaping (Johnson L, 2016) who stated, subsequent to his own research, that he was completely unable to identify confirmatory evidence for PG being used in nebuliser therapy. He stated that the claim is fundamentally “misleading”, and that, “as many vapers will know – some people find PG very irritating to the throat”. Johnson continued to speculate on the genesis of the claim:

“As for why this argument has gained so much traction, my only guess is for the same reason I want it to be true: it’s so powerful to be able to say, “well, even asthmatics can inhale PG without problems, so worrying about it in e-cig vapor is
“silly.” But when you really want something to be true, you don’t have much motivation to go and check out whether or not it’s really the case” [Johnson L, 2016]

Is it safe to inhale vapourised flavouring chemicals?

There are now some 8000 beguiling and often child-friendly flavours being sold in e-juice [Allen et al, 2016; Barrington-Trimis et al, 2014]. These have mostly been approved for ingestion as food additives, but have never been approved for inhalation. The U.S. flavouring industry has said about this issue:

“The manufacturers and marketers of ENDS, and all other flavored tobacco products, and flavor manufacturers and marketers, should not represent or suggest that the flavor ingredients used in these products are safe because they have FEMA GRAS™ status for use in food because such statements are false and misleading.” [see https://www.femaflavor.org/safety-assessment-and-regulatory-authority-use-flavors-focus-electronic-nicotine-delivery-systems]

For some flavourants, for example cinnamon, there is already evidence for cytotoxicity [Behar et al, 2014] and for the very commonly utilised additive diacetyl, which produces a pleasant, buttery taste in e-liquid, there is an association with the causation of the non-reversible respiratory condition Bronchiolitis Obliterans [Farsalinos et al, 2015; Allen et al, 2016]. The English National Centre for Smoking Cessation and Training has already recommended that users avoid cinnamon and diacetyl flavoured e-liquid [NCSCT, 2016] but these are still on sale. Cherry flavoured ENDS fluids have also been demonstrated, via the inhalation of the irritant benzaldehyde, to be a potential concern for long term users [Kosmider et al, 2016].

Our knowledge of the impact of long term inhalation, many times a day over many years, of vapour arising from the heating of these chemicals is in its infancy. We therefore recommend adopting the precautionary principle to issues related to the safety of ENDS.

What do we know about explosions that occur with vapourisers?

There are continuing reports of reports of dramatic explosions occurring with ENDS from around the world. Those working in trauma care have published case-series of serious burns and injuries and shotgun like injuries arising from these explosions [e.g. Jiwani et al, 2017; Bohr S et al, 2016; Shastry S et al, 2016]

There are now dozens of cases reported in medical journals of burns and other injury related to lithium-ion battery powered device malfunction. Explosive malfunction causes
three complications: blast injury, thermal burn from the device and superheated vaping liquid and corrosive burn from lithium. (Brownson et al, 2016)

Broadly, device-related injuries can be grouped into those when the device is not in use, most commonly when in a trouser pocket, and when in use near or in the mouth. Explosions in the vicinity of the mouth during use are potentially catastrophic. Reported consequences include major dental injury (Brooks et al, 2017; Harrison et al, 2016), injury to soft tissues in the mouth and pharynx and even fractures of C1/C2 vertebrae (Norii and Plate, 2017).


Burn injuries are becoming so frequent that a classification system has been proposed (Patterson et al 2017). Burns have most commonly been reported in the thigh area. Whereas first aid for thermal burn generally is based on water application, this may worsen the situation with lithium burn. The total burn area averages less than 10% but may include the external genitalia - an area that represents particular challenges for burns surgery and of course important long-term physical and psychological harms for the (generally) young person affected.
ENDS advocates often note that other lithium battery-powered items like mobile phones and laptops have also exploded (often in far greater numbers than have ENDS), apparently implying from this that there is no need for concern about the safety of ENDS and their batteries. Explosions have occurred in pockets as well as during inhalation.[11]

When mobile phones and computers explode, we see responsible industries suspend sales or enact global recalls, until they have rendered the product safe, as happened with the Samsung Galaxy Note 7 in 2016. At the time Samsung initiated its global recall, there had been only 35 cases of battery-related explosions - much less even than the number of cases of injury from exploding ENDS devices that have now been reported in medical journals alone.

In 2006, Dell computers recalled 4 million batteries[12] and HP recalled 101,000 batteries in January 2017. We are very pleased that use of ENDS is banned on nearly every airline. There has been one report of an ENDS explosion and fire on board an aircraft (in an overhead locker) [13]. Fortunately

---


this was extinguished by crew. An ENDS explosion in stowed luggage where it could not be extinguished could have catastrophic consequences.

The lack of regulatory standards for ENDS and their components stands in stark contrast to these other products.
**Term of Reference #3. International approaches to legislating and regulating the use of E-cigarettes and personal vaporisers**

Assertions have been made that there is widespread support for light touch regulation of ENDS, and that Australia is an outlier in its present policy position. This support is, however, far from universal among nations, health authorities and agencies. It is misleading to portray Australia as an outlier.

The “light touch” position is naturally favoured by those involved in ENDS manufacture and commerce, and accordingly is an approach supported by those conflicted with commercial objectives. It is also favoured by many who vape today.

Some experts have argued that that analysis of the International Tobacco Control Four Country surveys (i.e. data from the United States and Canada, the United Kingdom and Australia), demonstrate that:

> “Use of ECs in the real world during a quit attempt appears only effective for sustaining smoking abstinence in a less restrictive EC environment suggesting that the benefits of ECs [electronic cigarettes] for smoking cessation are likely highly dependent on the regulatory environment” [Yong et al, 2017].

This analysis has been strongly critiqued by Benmarhnia et al (2017), who identified that

> “there are at least three limitations in this paper that severely temper the conclusions reached by the authors and, in our view, cannot be addressed by the supporting data. Given the importance of the research question, it is equally important that firm conclusions be generated from appropriate data.”

As they argued:

> “[firstly] . . the measurement of e-cigarette use was only valid in one of the ten waves of the data used” . . . secondly, that “the analyses suffer from inadequate sample size, drawing into question the generalizability of the sample to the population they are purported to represent. For instance, there are only 50 respondents from either Canada or Australia who reported using an e-cigarette over the entire 11-year period” . . . and thirdly, that “the authors consider how the association of e-cigarette use with 30-day cigarette abstinence varies across countries categorized according to their regulatory environment . . ., but the validity
of this proposed singular distinction has not been demonstrated” [Benmarhnia et al, 2017]

The Johns Hopkins Bloomberg School of Public Health has summarised ENDS regulation of 123 countries in a comprehensive website (see [http://globaltobaccocontrol.org/node/14052](http://globaltobaccocontrol.org/node/14052)). This summary reported that the sale of all types of ENDS is banned in 26 countries, 18 countries regulate ENDS as medicinal products, 26 countries regulate ENDS as tobacco products (or imitation/derivative/substitute products) and four countries regulate ENDS containing nicotine as poisons. Use of ENDS is banned in three countries (Cambodia, Jordan and the United Arab Emirates). As of February 2016, 71 countries had been identified that regulate ENDS.

Global
Among leading health agencies with strong concerns about ENDS are the World Health Organization, the US Surgeon General, the US FDA, Australia’s National Health and Medical Research Council and the TGA.

USA
- US Food and Drug Administration (see regulations here [https://www.fda.gov/tobaccoproducts/labeling/productsingredientscomponents/ucm456610.htm#regulation](https://www.fda.gov/tobaccoproducts/labeling/productsingredientscomponents/ucm456610.htm#regulation))

These 51 US groups listed below have all urged the US political administration to support the Food and Drug Administration’s regulation of ENDS (see [http://www.tobaccofreekids.org/press_releases/post/2017_05_17_fda](http://www.tobaccofreekids.org/press_releases/post/2017_05_17_fda))

Action on Smoking & Health
American Academy of Family Physicians
American Academy of Oral and Maxillofacial Pathology
American Academy of Pediatrics
American Association for Cancer Research
American Association for Dental Research
American Association for Respiratory Care
American Cancer Society Cancer Action Network
American College of Cardiology
American College of Occupational and Environmental Medicine
American College of Physicians
American College of Preventive Medicine
American Congress of Obstetricians and Gynecologists
American Dental Association
American Heart Association
American Lung Association
American Medical Association
American Psychological Association
American Public Health Association
American School Health Association
American Society of Addiction Medicine
American Society of Clinical Oncology
American Thoracic Society
Americans for Nonsmokers’ Rights
Asian Pacific Partners for Empowerment, Advocacy and Leadership
Association of Women’s Health, Obstetric & Neonatal Nurses
Big Cities Health Coalition
Campaign for Tobacco-Free Kids
ClearWay Minnesota
Community Anti-Drug Coalitions of America
Eta Sigma Gamma - National Health Education Honorary
March of Dimes
National African American Tobacco Prevention Network
National Association of County and City Health Officials
National Association of Pediatric Nurse Practitioners
National Center for Health Research
National Hispanic Medical Association
National Network of Public Health Institutes
National Physicians Alliance
Oncology Nursing Society
Prevention Institute
Prevention Partners
Public Health Solutions
Society for Cardiovascular Angiography and Interventions
Society for Public Health Education
Students Against Destructive Decisions
The Society of State Leaders of Health and Physical Education
Tobacco Control Legal Consortium
Trust for America’s Health
Truth Initiative
In Australia, the NHMRC, the Cancer Council, the Heart Foundation, the Australian Medical Association, Lung Foundation Australia, Thoracic Society of Australia and New Zealand and the Public Health Association of Australia and New Zealand have all expressed support for TGA regulation of ENDS.

**UK**

The Public Health England agency claims there is a consensus in England regarding the safety and usefulness of ENDS. This ignores the fact that prominent health organisations and scientists within the UK are not part of it, and have demonstrably disagreed with at least some of PHE’s position. For example:

1. The British Heart Foundation: “There is a lack of empirical research regarding the effectiveness of e-cigarettes as a smoking cessation aid . . .”.

2. Public Health Wales: “Confectionery-like’ flavours of e-liquid should not be permitted, in order to reduce the appeal of ENDS to children and young people”.

3. ASH Scotland e.g. “… widely varying estimates demonstrate the difficulty of attributing a meaningful value to {the health} risk {of e-cigarettes} without long-term studies of health of e-cig users.”

4. Professor Helen Stokes-Lampard, Chair of the Royal College of General Practitioners “Vaping should not be allowed in public places where cigarette smoking is banned”.

5. The British Medical Association: “There is some evidence in other countries that e-cigarettes may be acting as a gateway to smoking” [http://www.bma.org.uk/-/media/files/pdfs/working%20for%20change/policy%20and%20lobbying/pa-e-cigarettesbriefing-03-12-2014.pdf](http://www.bma.org.uk/-/media/files/pdfs/working%20for%20change/policy%20and%20lobbying/pa-e-cigarettesbriefing-03-12-2014.pdf) (see Term of Ref 5 below)

6. The Royal Pharmaceutical Society: “We have expressed concern over possible safety issues of using e-cigarettes, as well as a lack of evidence of their efficacy when used for smoking cessation” . . . “We recommend that policy-makers must do everything they can to avoid a new generation of people becoming addicted to nicotine. This is particularly important in light of the current lack of evidence in relation to long-term health effects of using e-cigarettes, and their secondhand emissions”
   [https://www.rpharms.com/making-a-difference/policy-a-z/e-cigarettes](https://www.rpharms.com/making-a-difference/policy-a-z/e-cigarettes)
7. English toxicologists Dr Robert Combes and Emeritus Professor Michael Balls’ comprehensive critique of the position of Public Health England is self-explanatory [Combes & Balls, 2015].

Seven policy approaches to ENDS regulation were outlined in Section 4 of a report prepared for the Commonwealth Department of Health in 2016 (the Committee secretariat has been sent a copy).

These policy approaches are not meant to be mutually exclusive.

**The seven possible policy approaches are as follows:**
- Policy approach 1: Maintain the status quo
- Policy Approach 2: Increase awareness and enforcement of and compliance with existing legislation
- Policy approach 3: Regulate ENDS as medicines
- Policy approach 4: Regulate ENDS as tobacco products
- Policy approach 5: Regulate ENDS as consumer products
- Policy approach 6: Develop an ENDS regulatory framework
- Policy approach 7: Adopt measures to ban ENDS

We commend that report for the Committee’s consideration (Note: author Chapman contributed a section to that report)
Term of Reference #4: The appropriate regulatory framework for E-cigarettes and personal vaporisers in Australia

Australia introduced modern approaches to drug regulation in 1963 following the thalidomide tragedy. The Therapeutic Goods Administration (TGA) and its predecessors have had responsibility for the evaluation, regulation and scheduling of any product where therapeutic claims are made.

The TGA

“safeguards and enhances the health of the Australian community through effective and timely regulation of therapeutic goods”. It is well recognised as a crucial and meticulous component of Australia’s health system. Its activities include “ensuring that therapeutic goods available for supply in Australia are safe and fit for their intended purpose”. The full role and approaches taken by the TGA are set out on the TGA website (https://www.tga.gov.au/)

We have consistently argued that ENDS should remain subject to the TGA process. Nobody could take seriously any suggestion that they are not being promoted as cessation aids. There is simply no worthwhile case for bypassing the TGA other than that some groups or individuals may not be comfortable with the outcomes of rigorous, objective scientific review.

Further, bypassing the TGA on the basis of lobbying by sectional interests would set a potentially disastrous precedent, indicating a lack of confidence in the TGA and opening the door to similar lobbying and bypassing for many other products where companies or individuals wish to avoid proper scrutiny.

Quack claims about alleged cures for deadly and common diseases like cancers, HIV/AIDS and asthma have long been with us. But we do not allow those with an alleged cancer cure to by-pass the TGA assessment process and sell and promote a substance as cancer-curing simply on the strength of either commercial lobbying or emotional rhetoric.

We are aware of an argument that if ENDS makers had to convince the TGA on safety and effectiveness, only the pharmaceutical and tobacco industries could afford to conduct the research to the standards required. This in itself is open to debate. But the alternative -- to allow any backyard “kitchen chemist” maker of vaping equipment and ingredients to sell
and promote their products without TGA regulation – is an irresponsible proposal that would both put the health of consumers at risk and set a very dangerous precedent.

As noted in an article in the Medical Journal of Australia co-authored by McKee, Chapman and Daube:

“In Australia, anyone considering importing or supplying e-cigarettes as a cessation aid must submit an application to the Therapeutic Goods Administration (TGA) with evidence of their safety and efficacy. The TGA then considers the evidence before determining whether the product may be sold, and, if so, under what conditions.”

[McKee, Chapman & Daube, 2016]

This is the approach that should be taken in relation to ENDS. It may be important to stress in this context that our position is not, as has sometimes been falsely stated, simple “opposition” to new approaches. It is that proper processes should be followed; the role of the TGA should be supported; and any determinations by the TGA should be respected.

In 2016-17 the TGA considered proposals to bypass poison controls to enable access to liquid nicotine for vaping. Following extensive consultations, submissions and reviews the TGA concluded that “the scheduling for nicotine remains appropriate”. (see https://www.tga.gov.au/book-page/21-nicotine-0 )The TGA comments and final decisions set out a wide range of concerns and conclusions leading to this decision, including those summarised under the headings “Delegates’ interim decision” and “Delegates’ final decision”. We recognise that some who make submissions to the Inquiry may not like the verdict of this impartial and authoritative referee, but we urge the Committee to recognise, support and uphold the integrity and authority of the TGA.

It is further relevant to note that the nation’s highest medical authority, the National Health and Medical Research Council, has also carefully reviewed the evidence on e-cigarettes/ENDS, with two CEO statements, first in 2015, then an updated statement as recently as April 2017. The 2017 statement reports that while “Electronic cigarettes (e-cigarettes, also known as electronic nicotine delivery systems (ENDS) or electronic non-nicotine delivery systems (ENNDS)) are often marketed as a method to assist smokers to quit, or as a ‘safe alternative’ to conventional tobacco cigarettes”, “......there is currently insufficient evidence to support claims that e-cigarettes are safe and further research is needed to enable the long-term safety, quality and efficacy of e-cigarettes to be assessed”.

We recognise that, as in relation to the TGA, some groups or individuals may not be comfortable with the outcomes of rigorous, objective scientific review, but that should not be allowed to undermine the authority of the NHMRC or its advice, any more than this
should occur on the basis of representations from commercial interests or enthusiasts in any other area.

**Refusing to accept the umpire’s decision**

Indeed, we find it disturbing that there are clearly some who wish to bypass both the TGA and NHMRC despite the crucial role both these bodies play in ensuring that Australian governments and community receive the best possible advice, and that the health of the public is well protected, with appropriate safeguards.

The TGA is in every sense Australia’s national “umpire” on claims about therapeutic product safety and efficacy. Its processes and decisions over decades have given Australia one of the world’s best and most envied therapeutic regulatory systems. Those who have been working to try and have the TGA circumvented as this umpire are challenging its authority on the flimsiest of pretexts. They have refused to accept the TGA umpire’s decision, a course of action which brings them great discredit.

Many of those who have been prominent in this exercise have little if any serious track record or experience in population-focused tobacco control. They, and some from overseas, may not be aware of the roles and critical importance of the TGA and NHMRC.

**ENDS use in Australia today: very low**

In considering policy options for ENDS, the we believe that the Committee should be mindful of the size of the likely demand for ENDS, and also of the potential risks of ENDS becoming popular with Australian children and young people should their accessibility and promotion move in the directions being advocated by the ENDS and tobacco industries.

ENDS are widely available for sale in Australia, although e-juice containing nicotine must be imported. This is very easily done (as easily as ordering books, clothing or other consumer goods is today on-line). Despite this, ENDS use is a very marginal activity in Australia today. The AIHW 2013 national survey (the largest survey on smoking and ENDS use available for Australia) reported that:

<table>
<thead>
<tr>
<th>Year</th>
<th>Ever used e-cigarettes</th>
<th>Among daily smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>4.5% of all persons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.8% of 14+ non-smokers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.8% of 14+ smokers</td>
<td></td>
</tr>
</tbody>
</table>
12.2% of the Australian population aged 14 years and over smoke daily. Yet only 1.5% of these are vaping daily (ie 0.186% of all Australians aged 14 and over). It is far more common (17.8 times more common) for daily smokers to have experimented with or used and then stopped using ENDS than for daily smokers to be using them today.

Only 0.8% of ex-smokers are vaping. We do not know what proportion of these are recent smokers who quit and are now vaping, and what proportion may be longer term ex-smokers who took up vaping long after quitting.

There are two main Australian on-line forums for vapers; Aussie vapers (http://forums.aussievapers.com/forum.php with 1,781 active members as at 26 June, 2017 and Vaper Cafe www.vapercafeaustralia.com/ with only 931 members on the same date. Many members belong to both. It is not known how many of these are Australian members and how many are from abroad.

These numbers provide no evidence that anything other than transient curiosity vaping is widespread in Australia. By far the largest numbers of people who have vaped are smokers who have tried it a few times and did not then go on to vape regularly (some 20% of smokers). There is no evidence that there are large numbers of smokers in Australia who want to vape but cannot do so, given the ease with which those who are vaping now are able to obtain both vaping equipment and nicotine containing e-juice.
Term of Reference #5. Any other related matter

Two issues deserve the Committee’s careful attention.

Does ENDS use predict later uptake of smoking?

Earlier, we were critical of claims made by those involved in ENDS manufacture and commerce that they had no interest in seeing children use ENDS. We argued that this is a commercially disingenuous claim, made entirely for public relations purposes. No industry concerned for its longevity would claim that it had no interest in fomenting strong interest in its products among future users.

Australia currently has the lowest rate of smoking among children ever recorded in this country. Only 2% of Australian children and young people aged 12-17 have ever smoked 100 or more cigarettes (see http://www.aihw.gov.au/2016-national-drug-strategy-household-survey/).

This is the lowest level ever recorded and is a huge testimony to the effectiveness of Australian tobacco control over the decades. Given that there is no evidence of any significant use of nicotine replacement therapy among youth, we are confident that regular exposure to nicotine in any form is fast becoming a thing of the past among Australian youth.

This is disastrous news for both tobacco companies and ENDS companies alike. With the former, the search for acceptable routes into nicotine addiction that might see young ENDS users also start smoking would be front of mind.

Appendix 3 is a Powerpoint presentation of evidence prepared by a colleague, A/Prof Stacey Carter, found in tobacco industry documents, about their intense interest in children and the duplicitous efforts they took to publicly deny that interest. All companies will have done elementary calculations about the need to attract starters among young people to expand the user base. Why contain the appeal of ENDS just to the dwindling number of smokers when the prospects of interesting the far more numerous non-smokers beckon?

ENDS as presursor or catalyst to smoking

As at February 2017, there were nine longitudinal studies suggesting that children starting nicotine use with ENDS and transitioning to smoking conventional cigarettes [Soneji et al, 2017]. These studies all considered youth who had not smoked a conventional cigarette, and then compared smoking between youth who did and did not use ENDS at baseline.
Critics of these studies often dismiss them by saying that all they show is that “children who are going to smoke in the future, will smoke in the future”. They argue that all these studies do is show that those children likely to become smokers are do so. However, such studies do attempt to control for relevant confounders:

“They [the critics] miss the fact that the studies controlled for variables that are defining characteristics of high-risk youth, including risk-taking, impulsiveness, negative affect, low parental support, and affiliation with deviant peers, and the effect of e-cigarette use for smoking onset was independent of these confounders. Moreover, recent research with different designs has shown that e-cigarettes are most strongly related to smoking onset among lower-risk adolescents, thus specifically contradicting the confounding hypothesis.” (Wills, 2017)

The extent of this gateway or catalytic effect of initial ENDS use on later smoking uptake has now been shown in a meta-analysis of all these studies, appropriately adjusting and allowing for demographic, psychosocial, and behavioral risk factors for cigarette smoking, found that the odds of subsequent cigarette smoking were quadrupled among e-cigarette users [Soneji et al, 2017]. E-cigarette users are 5 times more likely to smoke but this is reduced to only a three-fold increased risk after adjusting for the relevant confounding factors typically highlighted by critics. Unless critics of these findings propose another confounding factor to which they have not previously alluded the Soneji et al evidence is compelling.

These findings and opinions further substantiate the concerns raised regarding the use of electronic cigarettes by youth and young adults in the US by the Surgeon General in late 2016, a comprehensive scientific report, generated from the input of approximately 150 experts in this field [US Surgeon General, 2016].

We are completely unimpressed the with the circularity of the response often made by ENDS advocates to findings about the possibility that ENDS use may act as a catalyst to subsequent smoking. A typical glib reply is that “kids who are going to try stuff, try stuff” made to any suggestion of vaping being an important predisposer to smoking. Here, they act as if the possibility that we may ever identify critical factors other than a circular “those who will smoke, will smoke” insight that increase the probability of someone taking up smoking is somehow preposterous.

We have had no problem with research that has often identified factors that promote smoking uptake and which governments then try to influence with policy or programs (eg: low price, tobacco advertising, parental smoking, smoking by teachers, etc.). But when
research suggests that using ENDS might condition some children into thinking “I wonder what the ‘real thing’ [ie smoking] is like?”, we see some extraordinary responses.

Professor Peter Hajek, a long time advocate of ENDS, has said about the Soneji et al meta-analysis:

“People who drink white wine are more likely to also try red wine than teetotallers, but common sense would not suggest that this means that removing the white will reduce the drinking of the red.”


This is an inept analogy, as one of the authors of the JAMA meta-analysis exposed with the following salient point.

"Young people report that there is a lot of pressure among e-cigarette only users to smoke a 'real' cigarette. It may be somewhat analogous to the fact that teens who use flavored alcohol are often pressured socially to step up their game to harder forms of alcohol." (see https://www.reuters.com/article/us-health-teens-vaping-idUSKBN19H292)

ENDS, with their many teen-friendly flavours, their less harsh “throat grab”, the ease with which they can be used inconspicuously (little smell, rapidly secretable), and their hyped “almost totally safe’ propaganda have considerable appeal to youth compared with smoking. But, just as a large proportion of adults who experiment with ENDS do not continue using them, finding them unsatisfying [eg:Pepper et al 2014] so too it is likely that some young people may move on to cigarettes, with ENDS abandoned as “training wheels”.

Schneider & Diehl (2015) considered the inadequacies of crude “gateway” hypotheses and posited a compelling “catalyst” model for researchers and policy makers to consider about how initial ENDS use may stimulate later smoking. Their

“results indicate that the perceived health risks, specific product characteristics (such as taste, price and inconspicuous use), and higher levels of acceptance among peers and others potentially make e-cigarettes initially more attractive to adolescents than tobacco cigarettes. Later, increasing familiarity with nicotine could lead to the reevaluation of both electronic and tobacco cigarettes and subsequently to a potential transition to tobacco smoking.”
ENDS advocates have pointed out that cross-sectional surveys of smoking in the USA and England show that as ENDS use is rising, smoking prevalence is falling in adolescents. From this, they imply that there therefore cannot be any significant problem of ENDS use causing an increase in smoking among youth. But this does not follow at all.

There are multiple reasons for both the rise and the fall in smoking prevalence. If the impact of all factors driving smoking down in youth is greater than the impact of any putative ENDS “gateway” effect on smoking, smoking prevalence among youth would be falling.

But such a fall could nonetheless mask considerable smoking uptake caused by any ENDS gateway effects that were not widespread enough to stop the net fall in smoking prevalence still occurring. For this reason, longitudinal cohort studies such as those meta-analysed by Soneji et al (2017) are critical in understanding whether ENDS are an important catalyst for smoking among youth. As we have emphasised, that analysis shows that E-cigarette users are 5 times more likely to smoke but this is reduced to only a three-fold increased risk after adjusting for the relevant confounding factors typically highlighted by critics.

**Should restrictions be placed on where vaping can occur?**

Policy on smoking in public spaces is a state and territory matter, so beyond the remit of this Committee, other than in locations controlled by Commonwealth law such as some airports. In Appendix 4 [Chapman, Daube, Maziak, 2017], we set out several reasons why ENDS use should not be allowed in any setting where cigarette smoking is not allowed. These include:

- Exposure of the public to harmful particles, particularly in enclosed environments with high concentration of persons vaping (see this video [https://www.youtube.com/watch?v=VxiEZeFEZzs](https://www.youtube.com/watch?v=VxiEZeFEZzs) and the Figure below
- Risks of catastrophic explosions (especially on aircraft -- see earlier)
- Triggering relapse in former smokers
- Renormalising the smoking “performance”
Both the American Indoor Hygiene Association's 2014 *White Paper: Electronic Cigarettes in the Indoor Environment*, subsequent to their full independent scientific review here [https://www.aiha.org/government-affairs/PositionStatements/Electronic%20Cig%20Document_Final.pdf](https://www.aiha.org/government-affairs/PositionStatements/Electronic%20Cig%20Document_Final.pdf) and the American Society of Heating Refrigeration and Air-conditioning Engineers 2016 *Standards 62.1 & 62.2; The Standards for Ventilation and Indoor Air Quality* here [https://www.ashrae.org/resources--publications/bookstore/standards-62-1--62-2](https://www.ashrae.org/resources--publications/bookstore/standards-62-1--62-2) confirm that there are potential health risks and concerns related to bystanders and passive vaping in indoor public areas, especially for susceptible groups such as the old and young, those with pre-existing health issues e.g. cardiac and respiratory, pregnant mothers. They strongly recommend that e-cigarettes should be treated the same as conventional cigarettes in such areas. The American Indoor Hygiene Association stated that:

“e-cigarettes are not emission-free and that their pollutants could be of health concern for users and those who are exposed secondhand. ... [T]heir use in the indoor environment should be restricted, consistent with current smoking bans, until and unless research documents that they will not significantly increase the risk of adverse health effects to room occupants” [AIHA, 2014].

Data confirm the need for this precautionary policy standpoint, showing that levels of fine particulate matter (PM$_{2.5}$) in a large hotel event room (4023 m$^3$) increased from 2-3 µg/m$^3$...
to as high as 819 µg/m$^3$ (interquartile range: 761-975 µg/m$^3$) when 59 to 86 people were using their e-cigarettes (Soule et al, 2017): a level comparable to a very smoky bar or casino. These levels substantially exceeded the US Environmental Protection Agency annual time-weighted standard for PM$_{2.5}$ of 12µg/m$^3$.

Tangentially, It has been argued by Bauld et al (2016) that

“if and when vapour products with a medicinal license become available, it will be important to allow their use indoors, just as asthma inhalers, which dispense a drug and propellants into the atmosphere, can be used indoors.”

The comparison and conclusion here is fundamentally inappropriate, and misleading. Newman et al showed, as long ago as 1991, that the amount of dosed drug exhaled by asthmatics using inhalers ranged from just 0.2%-1.7% across different puffing behaviours [Newman et al, 1991]. A typical person who uses an asthma reliever therapy puffer e.g. Salbutamol 100mcg would not normally be recommended to use it more than 2 puffs four times a day (8 puffs/day), as the UK National Institute for Health and Clinical Excellence recommend the prescription of salbutamol, with reference to British National Formulary (https://bnf.nice.org.uk/drug/salbutamol.html#indicationsAndDoses ). Conversely, vapers can take up to, and therefore exhale, 610 puffs a day, with an average of around 200 puffs [Martin et al, 2016].

There is simply no comparison between what the asthma medication and propellant, and what one or even a few asthmatics might exhale into, for example, a crowded bar over a few hours, and what potentially dozens of vapers could generate in the sort of exuberant cloud chasing sessions that vaping in bars can entail. Furthermore, unlike vapers, asthmatics obviously do not participate in asthma puffer social events and competitions.

**In conclusion:**

Smoking remains Australia’s largest single preventable cause of death and disease.

Trends among adults and children in Australia have been encouraging over time as a result of consensus action based on recommendations from health authorities. As a consequence, Australia is one of the world’s leading countries in reducing smoking in adults and onset of smoking among children and young people. It is especially encouraging that 98% of those aged 12 – 17 are classified as never-smokers.
There is a strong evidence base for action that will further reduce smoking and its harms in both the community as a whole and disadvantaged groups.

There should be caution about introducing new products, with inevitable consequent promotion, that may distract from further evidence-based action, introduce new risks to the community, and undermine the progress that has been made.

The evidence supporting e-cigarettes as a cessation aid is weak; there is some evidence that they may be counter-productive; and there are significant concerns about potential harms that may arise from use of e-cigarettes and related products, including renormalising smoking behaviour and acting as a catalyst for smoking among children and young people. There is further concern at the enormous range of products and flavours being developed and promoted, with lack of information as to their consequences.

Leading health authorities such as the World Health Organization and the US Surgeon General have supported the case for a cautionary approach, which has also been adopted by many other countries.

The National Health and Medical Research Council (NHMRC) has recently concluded that “there is currently insufficient evidence to support claims that e-cigarettes are safe and further research is needed to enable the long-term safety, quality and efficacy of e-cigarettes to be assessed”. The Therapeutic Goods Administration (TGA) has also recently concluded that “unlike Nicotine Replacement Therapy (NRT) products, which have been rigorously assessed for efficacy and safety and, therefore, approved by the Therapeutic Goods Administration for use as aids in the withdrawal from smoking, no assessment of electronic cigarettes has been undertaken and, therefore, the quality and safety of electronic cigarettes is not known.”

E-cigarettes, as any other products claimed or promoted as therapeutic products to help smokers quit or reduce their harms should remain subject to the processes of the TGA, whose role, independence and integrity should be strongly supported, as should that of the NHMRC.

Recognising Article 5.3 of the WHO Framework Convention on Tobacco Control, to which the Australian Government is a signatory, any considerations on this issue should be protected from direct or indirect influences by commercial and other vested interests of the tobacco industry.
Appendix 1: Recent publications reporting findings about potential harm of exposure to e-cigarettes

Electronic cigarette aerosols suppress cellular antioxidant defenses and induce significant oxidative DNA damage.
Ganapathy V, Manyanga J, Brame L, McGuire D, Sadhasivam B, Floyd E, Rubenstein DA, Ramachandran I, Wagener T, Queimado L.

BACKGROUND:
Electronic cigarette (EC) aerosols contain unique compounds in addition to toxicants and carcinogens traditionally found in tobacco smoke. Studies are warranted to understand the public health risks of ECs.

OBJECTIVE:
The aim of this study was to determine the genotoxicity and the mechanisms induced by EC aerosol extracts on human oral and lung epithelial cells.

METHODS:
Cells were exposed to EC aerosol or mainstream smoke extracts and DNA damage was measured using the primer anchored DNA damage detection assay (q-PADDA) and 8-oxo-dG ELISA assay. Cell viability, reactive oxygen species (ROS) and total antioxidant capacity (TAC) were measured using standard methods. mRNA and protein expression were evaluated by RT-PCR and western blot, respectively.

RESULTS:
EC aerosol extracts induced DNA damage in a dose-dependent manner, but independently of nicotine concentration. Overall, EC aerosol extracts induced significantly less DNA damage than mainstream smoke extracts, as measured by q-PADDA. However, the levels of oxidative DNA damage, as indicated by the presence of 8-oxo-dG, a highly mutagenic DNA lesion, were similar or slightly higher after exposure to EC aerosol compared to mainstream smoke extracts. Mechanistically, while exposure to EC extracts significantly increased ROS, it decreased TAC as well as the expression of 8-oxoguanine DNA glycosylase (OGG1), an enzyme essential for the removal of oxidative DNA damage.

CONCLUSIONS:
Exposure to EC aerosol extracts suppressed the cellular antioxidant defenses and led to significant DNA damage. These findings emphasize the urgent need to investigate the potential long-term cancer risk of exposure to EC aerosol for vapers and the general public.
**E-cigarette induced toxicological effects that can raise the cancer risk.**

Abstract

BACKGROUND:
Electronic cigarette (EC) aerosols contain unique compounds in addition to toxicants and carcinogens traditionally found in tobacco smoke. Studies are warranted to understand the public health risks of ECs.

OBJECTIVE:
The aim of this study was to determine the genotoxicity and the mechanisms induced by EC aerosol extracts on human oral and lung epithelial cells.

METHODS:
Cells were exposed to EC aerosol or mainstream smoke extracts and DNA damage was measured using the primer anchored DNA damage detection assay (q-PADDA) and 8-oxo-dG ELISA assay. Cell viability, reactive oxygen species (ROS) and total antioxidant capacity (TAC) were measured using standard methods. mRNA and protein expression were evaluated by RT-PCR and western blot, respectively.

RESULTS:
**EC aerosol extracts induced DNA damage in a dose-dependent manner, but independently of nicotine concentration.** Overall, EC aerosol extracts induced significantly less DNA damage than mainstream smoke extracts, as measured by q-PADDA. However, the levels of oxidative DNA damage, as indicated by the presence of 8-oxo-dG, a highly mutagenic DNA lesion, were similar or slightly higher after exposure to EC aerosol compared to mainstream smoke extracts. Mechanistically, while exposure to EC extracts significantly increased ROS, it decreased TAC as well as the expression of 8-oxoguanine DNA glycosylase (OGG1), an enzyme essential for the removal of oxidative DNA damage.

CONCLUSIONS:
**Exposure to EC aerosol extracts suppressed the cellular antioxidant defenses and led to significant DNA damage.** These findings emphasize the urgent need to investigate the potential long-term cancer risk of exposure to EC aerosol for vapers and the general public.
**Benzene formation in electronic cigarettes.**

Abstract

**BACKGROUND/OBJECTIVE:**
The heating of the fluids used in electronic cigarettes ("e-cigarettes") used to create "vaping" aerosols is capable of causing a wide range of degradation reaction products. We investigated formation of benzene (an important human carcinogen) from e-cigarette fluids containing propylene glycol (PG), glycerol (GL), benzoic acid, the flavor chemical benzaldehyde, and nicotine.

**METHODS/MAIN RESULTS:**
Three e-cigarette devices were used: the JUULTM "pod" system (provides no user accessible settings other than flavor cartridge choice), and two refill tank systems that allowed a range of user accessible power settings. Benzene in the e-cigarette aerosols was determined by gas chromatography/mass spectrometry. Benzene formation was ND (not detected) in the JUUL system. In the two tank systems benzene was found to form from propylene glycol (PG) and glycerol (GL), and from the additives benzoic acid and benzaldehyde, especially at high power settings. With 50:50 PG+GL, for tank device 1 at 6W and 13W, the formed benzene concentrations were 1.9 and 750 μg/m³. For tank device 2, at 6W and 25W, the formed concentrations were ND and 1.8 μg/m³. With benzoic acid and benzaldehyde at ~10 mg/mL, for tank device 1, values at 13W were as high as 5000 μg/m³. For tank device 2 at 25W, all values were ≤~100 μg/m³. These values may be compared with what can be expected in a conventional (tobacco) cigarette, namely 200,000 μg/m³. Thus, the risks from benzene will be lower from e-cigarettes than from conventional cigarettes. However, ambient benzene air concentrations in the U.S. have typically been 1 μg/m³, so that benzene has been named the largest single known cancer-risk air toxic in the U.S. For non-smokers, chronically repeated exposure to benzene from e-cigarettes at levels such as 100 or higher μg/m³ will not be of negligible risk.

**E-cigarettes as a source of toxic and potentially carcinogenic metals.**

Abstract

**BACKGROUND AND AIMS:**
The popularity of electronic cigarette devices is growing worldwide. The health impact of e-cigarette use, however, remains unclear. E-cigarettes are marketed as a safer alternative to cigarettes. The aim of this research was the characterization and quantification of toxic metal concentrations in five, nationally popular brands of cig-a-like e-cigarettes.

METHODS:
We analyzed the cartomizer liquid in 10 cartomizer refill samples for each of five brands by Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

RESULTS:
All of the tested metals (cadmium, chromium, lead, manganese and nickel) were found in the e-liquids analyzed. Across all analyzed brands, mean (SD) concentrations ranged from 4.89 (0.893) to 1970 (1540) μg/L for lead, 53.9 (6.95) to 2110 (5220) μg/L for chromium and 58.7 (22.4) to 22,600 (24,400) μg/L for nickel. Manganese concentrations ranged from 28.7 (9.79) to 6910.2 (12,200) μg/L. We found marked variability in nickel and chromium concentration within and between brands, which may come from heating elements.

CONCLUSION:
Additional research is needed to evaluate whether e-cigarettes represent a relevant exposure pathway for toxic metals in users.

Detection of 5-hydroxymethylfurfural and furfural in the aerosol of electronic cigarettes.

Abstract

SIGNIFICANCE:
The wide availability of sweet flavours has been hypothesised as a factor in the popularity of electronic cigarette (ECIG), especially among youth. Saccharides, which are commonly used to impart a sweet flavour to ECIG liquids, thermally degrade to produce toxic compounds, like aldehydes and furans. This study investigates the formation of furanic compounds in aerosols when ECIG liquid solutions of varying sweetener concentrations are vaped under different power and puff duration.

METHODS:
Liquids are prepared by mixing aqueous sucrose, glucose or sorbitol solutions to a 70/30 propylene glycol/glycerin solution. Aerosols are generated and trapped on filter pads using a commercially available ECIG operating at 4.3 and 10.8 W and 4 and 8 s puff duration. Extraction, elimination of matrix interference and quantification are achieved using novel
solid phase extraction and gas chromatography tandem mass spectrometry methods (GC-MS).

RESULTS:
Well-resolved GC peaks of 5-hydroxymethylfurfural (HMF) and furfural (FA) are detected. Both HMF and FA are quantified in the aerosols of sweet-flavoured e-liquids under various vaping conditions. Levels of furan emissions are significantly correlated with electric power and sweetener concentration and not with puff duration. Unlike saccharides, the formation of HMF and FA from a sugar alcohol is negligible.

CONCLUSIONS:
The addition of sweeteners to ECIG liquids exposes ECIG user to furans, a toxic class of compounds. Under certain conditions, the per-puff yield of HMF and FA in ECIG emissions is comparable to values reported for combustible cigarettes.

Nicotine and Carbonyl Emissions From Popular Electronic Cigarette Products: Correlation to Liquid Composition and Design Characteristics.
Nicotine Tob Res. 2016 Oct 7. pii: ntw280

Abstract

INTRODUCTION:
Available in hundreds of device designs and thousands of flavors, electronic cigarette (ECIG) may have differing toxicant emission characteristics. This study assesses nicotine and carbonyl yields in the most popular brands in the U.S. market. These products included disposable, prefilled cartridge, and tank-based ECIGs.

METHODS:
Twenty-seven ECIG products of 10 brands were procured and their power outputs were measured. The e-liquids were characterized for pH, nicotine concentration, propylene glycol/vegetable glycerin (PG/VG) ratio, and water content. Aerosols were generated using a puffing machine and nicotine and carbonyls were, respectively, quantified using gas chromatograph and high-performance liquid chromatography. A multiregression model was used to interpret the data.

RESULTS:
Nicotine yields varied from 0.27 to 2.91 mg/15 puffs, a range corresponding to the nicotine yield of less than 1 to more than 3 combustible cigarettes. Nicotine yield was highly correlated with ECIG type and brand, liquid nicotine concentration, and PG/VG ratio, and to a lower significance with electrical power, but not with pH and water content. Carbonyls, including the carcinogen formaldehyde, were detected in all ECIG aerosols, with total carbonyl concentrations ranging from 3.72 to 48.85 µg/15 puffs. Unlike nicotine, carbonyl concentrations were mainly correlated with power.

CONCLUSION:
In 15 puffs, some ECIG devices emit nicotine quantities that exceed those of tobacco cigarettes. Nicotine emissions vary widely across products but carbonyl emissions showed little variations. In spite of that ECIG users are exposed to toxicologically significant levels of carbonyl compounds, especially formaldehyde. Regression analysis showed the importance of design and e-liquid characteristics as determinants of nicotine and carbonyl emissions.

IMPLICATIONS:
Periodic surveying of characteristics of ECIG products available in the marketplace is valuable for understanding population-wide changes in ECIG use patterns over time.

**Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy.**

Abstract
As a modern phenomenon, there is currently limited understanding of the possible toxic effects and broader implications of electronic nicotine delivery systems (ENDS). Large volumes of aerosolized particles are inhaled during "vaping" and there are now an increasing number of case reports demonstrating toxic effects of ENDS, as well as human studies demonstrating impaired lung function in users. This article presents a case of respiratory bronchiolitis interstitial lung disease (RB-ILD) precipitated by vaping in a 33-year-old male with 10 pack years of traditional cigarette and prior treatment for mixed germ cell tumour. The patient had started vaping 10-15 times per day while continuing to smoke 10 traditional cigarettes per day. After 3 months of exposure to e-cigarette vapour, chest computed tomography demonstrated multiple new poorly defined pulmonary nodules with fluffy parenchymal opacification centred along the terminal bronchovascular units. Video-assisted thoracoscopy with lung biopsy of the right upper and right middle lobes was undertaken. The microscopic findings were overall consistent with RB-ILD.
A case demonstrates toxicity with use of ENDS on open lung biopsy with resolution of radiographic findings on cessation. We believe that this is the first case where open lung biopsy has demonstrated this and our findings are consistent with RB-ILD.

**Cytotoxic and Genotoxic Effects of Electronic Cigarette Liquids on Human Mucosal Tissue Cultures of the Oropharynx.**

Abstract

The popularity of electronic cigarettes (ECs) is rapidly growing and ECs are claimed to be an uncritically regarded alternative to conventional cigarettes. The mucosal tissue of the upper aerodigestive tract (UADT) is the first contact organ for xenobiotics such as liquids of ECs. The aim of this study is to investigate the bimolecular effects of e-liquids on human pharyngeal tissue cultures to evaluate whether e-liquids and their components present a risk factor for head and neck squamous cell carcinoma. Fresh tissue samples of healthy oropharyngeal mucosa were assembled into mucosal tissue cultures. Two fruit-flavored liquids (FLs), one tobacco-flavored liquid (TL) (all containing nicotine), and the corresponding base mixtures (free of nicotine and flavor) were used in three different dilutions. Cytotoxicity was assessed using the water-soluble tetrazolium-8 assay. DNA fragmentation was quantified using alkaline microgel electrophoresis. All liquids caused a significant reduction in cell viability. FLs especially showed a higher toxicity than TL. DNA fragmentation significantly increased by incubation with FL, whereas treatment with TL did not show serious DNA damage. **E-liquids are cytotoxic to oropharyngeal tissue, and some liquids can induce relevant DNA damage.** Thus, mutagenicity for mucosa of the UADT and e-liquids as risk factors for head and neck cancer cannot entirely be ruled out. Only the implementation of standards and regulations for liquid production and distribution can ensure a valid scientific investigation and assessment of carcinogenic potential of long-term EC use.

**Flavoring Compounds Dominate Toxic Aldehyde Production during E-Cigarette Vaping.**

The growing popularity of electronic cigarettes (e-cigarettes) raises concerns about the possibility of adverse health effects to primary users and people exposed to e-cigarette vapors. E-Cigarettes offer a very wide variety of flavors, which is one of the main factors that attract new, especially young, users. **How flavoring compounds in e-cigarette liquids affect the chemical composition and toxicity of e-cigarette vapors is practically unknown.**
Although e-cigarettes are marketed as safer alternatives to traditional cigarettes, several studies have demonstrated formation of toxic aldehydes in e-cigarette vapors during vaping. So far, aldehyde formation has been attributed to thermal decomposition of the main components of e-cigarette e-liquids (propylene glycol and glycerol), while the role of flavoring compounds has been ignored. In this study, we have measured several toxic aldehydes produced by three popular brands of e-cigarettes with flavored and unflavored e-liquids. We show that, within the tested e-cigarette brands, thermal decomposition of flavoring compounds dominates formation of aldehydes during vaping, producing levels that exceed occupational safety standards. Production of aldehydes was found to be exponentially dependent on concentration of flavoring compounds. These findings stress the need for a further, thorough investigation of the effect of flavoring compounds on the toxicity of e-cigarettes.

Toxicity evaluation of e-juice and its soluble aerosols generated by electronic cigarettes using recombinant bioluminescent bacteria responsive to specific cellular damages.
Bharadwaj S, Mitchell RJ, Qureshi A, Niazi JH.

Abstract

Electronic-cigarettes (e-cigarette) are widely used as an alternative to traditional cigarettes but their safety is not well established. Herein, we demonstrate and validate an analytical method to discriminate the deleterious effects of e-cigarette refills (e-juice) and soluble e-juice aerosol (SEA) by employing stress-specific bioluminescent recombinant bacterial cells (RBCs) as whole-cell biosensors. These RBCs carry luxCDABE-operon tightly controlled by promoters that specifically induced to DNA damage (recA), superoxide radicals (sodA), heavy metals (copA) and membrane damage (oprF). The responses of the RBCs following exposure to various concentrations of e-juice/SEA was recorded in real-time that showed dose-dependent stress specific-responses against both the e-juice and vaporized e-juice aerosols produced by the e-cigarette. We also established that high doses of e-juice (4-folds diluted) lead to cell death by repressing the cellular machinery responsible for repairing DNA-damage, superoxide toxicity, ion homeostasis and membrane damage. SEA also caused the cellular damages but the cells showed enhanced bioluminescence expression without significant growth inhibition, indicating that the cells activated their global defense system to repair these damages. DNA fragmentation assay also revealed the disintegration of total cellular DNA at sub-toxic doses of e-juice. Despite their state of matter, the e-juice and its aerosols induce cytotoxicity and alter normal cellular functions, respectively that raises concerns on use of e-cigarettes as alternative to traditional cigarette. The ability of
RBCs in detecting both harmful effects and toxicity mechanisms provided a fundamental understanding of biological response to e-juice and aerosols.

**A decade of e-cigarettes: Limited research and unresolved safety concerns.**  
Kaisar MA, Prasad S, Liles T, Cucullo L.  
Review.

Abstract  
It is well known that tobacco consumption is a leading cause of preventable deaths worldwide and has been linked to major diseases ranging from cancer to chronic obstructive pulmonary disease, atherosclerosis, stroke and a host of neurological/neurodegenerative disorders. In the past decade a number of alternative vaping products have hit the market, rapidly gaining consumers especially among the younger population. Electronic nicotine delivery systems or e-cigarettes have become the sought-after product due to the belief that they are much safer than traditional cigarettes. However, inadequate research and lack of regulatory guidelines for both the manufacturing process and the content of the vaping solution of the e-cigarette has become a major concern. Highly debated and unresolved questions such as whether e-cigarettes may help smokers quit and whether e-cigarettes will promote the use of nicotine among non-smokers add to the confusion of the safety of e-cigarettes. In this review article, we summarize the current understanding (and lack thereof) of the potential health impacts of e-cigarettes. We will also highlight the most recent studies (in vivo/in vitro) which seem to conflict with the broad safety claims put forward by the manufacturers. Finally, we provide potential solutions to overcome the research gap of the short and long-term health impact of e-cigarettes.
Appendix 2: Recent studies relevant to concerns about nicotine as a cancer promoter.


This Opinion article discusses emerging evidence of direct contributions of nicotine to cancer onset and growth. The list of cancers reportedly connected to nicotine is expanding and presently includes small-cell and non-small-cell lung carcinomas, as well as head and neck, gastric, pancreatic, gallbladder, liver, colon, breast, cervical, urinary bladder and kidney cancers. The mutagenic and tumour-promoting activities of nicotine may result from its ability to damage the genome, disrupt cellular metabolic processes, and facilitate growth and spreading of transformed cells. The nicotinic acetylcholine receptors (nAChRs), which are activated by nicotine, can activate several signalling pathways that can have tumorigenic effects, and these receptors might be able to be targeted for cancer therapy or prevention. There is also growing evidence that the unique genetic makeup of an individual, such as polymorphisms in genes encoding nAChR subunits, might influence the susceptibility of that individual to the pathobiological effects of nicotine. The emerging knowledge about the carcinogenic mechanisms of nicotine action should be considered during the evaluation of regulations on nicotine product manufacturing, distribution and marketing.


On theoretical grounds, nicotine has been implicated as a modifier of cancer progression. We investigated possible associations of smoking or use of Scandinavian moist snuff (snus) with survival after cancer among Swedish male construction workers. Snus use is associated with substantial exposure to nicotine but not to the combustion products in smoke. Among 336,381 workers with detailed information on tobacco use in 1971–1992, we observed 40,230 incident cancers. Complete follow-up through 2007 was accomplished through linkage to population and health registers. Hazard ratios (HRs) and 95% confidence intervals (CIs) for death from any cause, cancer-specific death and death from other causes were derived from Cox proportional hazards regression models adjusted for...
age at diagnosis, body mass index at study entry and period of diagnosis. Never users of any tobacco served as reference. Increased risks of cancer-specific death were observed both among exclusive smokers (HR\textsubscript{all cancer} 1.15, 95% CI: 1.10–1.21) and never-smoking snus users (1.15, 95% CI: 1.05–1.26). As regards deaths due to other causes, exclusive smokers had higher relative risks than exclusive snus users ($p = 0.03$). A history of tobacco use, even exclusive use of the seemingly benign snus, is associated with moderately increased cancer-specific mortality. Although nicotine might play a role, the mechanisms warrant further investigation.


Nicotine is a known risk factor for cancer development and has been shown to alter gene expression in cells and tissue upon exposure. We used Illumina® Next Generation Sequencing (NGS) technology to gain unbiased biological insight into the transcriptome of normal epithelial cells (MCF-10A) to nicotine exposure. We generated expression data from 54,699 transcripts using triplicates of control and nicotine stressed cells. As a result, we identified 138 differentially expressed transcripts, including 39 uncharacterized genes. Additionally, 173 transcripts that are primarily associated with DNA replication, recombination, and repair showed evidence for alternative splicing. We discovered the greatest nicotine stress response by HPCAL4 (up-regulated by 4.71 fold) and NPAS3 (down-regulated by -2.73 fold); both are genes that have not been previously implicated in nicotine exposure but are linked to cancer. We also discovered significant down-regulation (-2.3 fold) and alternative splicing of NEAT1 (lncRNA) that may have an important, yet undiscovered regulatory role. Gene ontology analysis revealed nicotine exposure influenced genes involved in cellular and metabolic processes. This study reveals previously unknown consequences of nicotine stress on the transcriptome of normal breast epithelial cells and provides insight into the underlying biological influence of nicotine on normal cells, marking the foundation for future studies.


Nowadays, tobacco smoking is the cause of ~5-6 million deaths per year, counting 31% and 6% of all cancer deaths (affecting 18 different organs) in middle-aged men and women, respectively. Nicotine is the addictive component of tobacco acting on neuronal nicotinic receptors (nAChR). Functional nAChR, are also present on endothelial, haematological and epithelial cells. Although nicotine itself is regularly not referred to as a carcinogen, there is an ongoing debate whether nicotine functions as a 'tumour promoter'. Nicotine, with its specific binding to nAChR, deregulates essential biological processes like regulation of cell
proliferation, apoptosis, migration, invasion, angiogenesis, inflammation and cell-mediated immunity in a wide variety of cells including foetal (regulation of development), embryonic and adult stem cells, adult tissues as well as cancer cells. Nicotine seems involved in fundamental aspects of the biology of malignant diseases, as well as of neurodegeneration. Investigating the biological effects of nicotine may provide new tools for therapeutic interventions and for the understanding of neurodegenerative diseases and tumour biology.


Despite continuous research efforts directed at early diagnosis and treatment of pancreatic cancer (PC), the status of patients affected by this deadly malignancy remains dismal. Its notoriety with regard to lack of early diagnosis and resistance to the current chemotherapeutics is due to accumulating signaling abnormalities. Hoarding experimental and epidemiological evidences have established a direct correlation between cigarette smoking and PC risk. The cancer initiating/promoting nature of cigarette smoke can be attributed to its various constituents including nicotine, which is the major psychoactive component, and several other toxic constituents, such as nitrosamines, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoic acid, and polycyclic aromatic hydrocarbons. These predominant smoke-constituents initiate a series of oncogenic events facilitating epigenetic alterations, self-sufficiency in growth signals, evasion of apoptosis, sustained angiogenesis, and metastasis. A better understanding of the molecular mechanisms underpinning these events is crucial for the prevention and therapeutic intervention against PC. This review presents various interconnected signal transduction cascades, the smoking-mediated genotoxicity, and genetic polymorphisms influencing the susceptibility for smoking-mediated PC development by modulating pivotal biological aspects such as cell defense/tumor suppression, inflammation, DNA repair, as well as tobacco-carcinogen metabolization. Additionally, it provides a large perspective toward tumor biology and the therapeutic approaches against PC by targeting one or several steps of smoking-mediated signaling cascades.


A substantial number of the world’s population continues to smoke tobacco, even in the setting of a cancer diagnosis. Studies have shown that patients with cancer who have a history of smoking have a worse prognosis than nonsmokers. Modulation of several physiologic processes involved in drug disposition has been associated with long-term
exposure to tobacco smoke. The most common of these processes can be categorized into the effects of smoking on cytochrome P450-mediated metabolism, glucuronidation, and protein binding. Perturbation in the pharmacokinetics of anticancer drugs could result in clinically significant consequences, as these drugs are among the most toxic, but potentially beneficial, pharmaceuticals prescribed. Unfortunately, the effect of tobacco smoking on drug disposition has been explored for only a few marketed anticancer drugs; thus, little prescribing information is available to guide clinicians on the vast majority of these agents. The carcinogenic properties of several compounds found in tobacco smoke have been well studied; however, relatively little attention has been given to the effects of nicotine itself on cancer growth. Data that identify nicotine's effect on cancer cell apoptosis, tumor angiogenesis, invasion, and metastasis are emerging. The implications of these data are still unclear but may lead to important questions regarding approaches to smoking cessation in patients with cancer.

Catassi A, Servent S, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res. 2008 Sep-Oct;659(3):221-31. doi: 10.1016/j.mrrev.2008.04.002. Epub 2008 Apr 11. The genotoxic effects of tobacco carcinogens have long been recognized, the contribution of tobacco components to cancerogenesis by cell surface receptor signaling is relatively unexplored. Nicotine, the principal tobacco alkaloid, acts through nicotinic acetylcholine receptor (nAChR). nAChR are functionally present on human lung airway epithelial cells, on lung carcinoma [SCLC and NSCLC] and on mesothelioma and build a part of an autocrine-proliferative network that facilitates the growth of neoplastic cells. Different nAChR subunit gene expression patterns are expressed between NSCLC from smokers and non-smokers. Although there is no evidence that nicotine itself could induce cancer, different studies established that nicotine promotes in vivo the growth of cancer cells and the proliferation of endothelial cells suggesting that nicotine might contribute to the progression of tumors already initiated. These observations led to the hypothesis that nicotine might be playing a direct role in the promotion and progression of human lung cancers. Here, we briefly overview the role and the effects of nicotine on pulmonary cell growth and physiology and its feasible implications in lung carcinogenesis.

Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol. 2008 Jan-Feb;30(1):1-19. Tobacco use in pregnancy is a leading cause of perinatal morbidity and contributes in major ways to attention deficit hyperactivity disorder, conduct disorders and learning disabilities that emerge in childhood and adolescence. Over the past two decades, animal models of prenatal nicotine exposure have demonstrated that nicotine is a neurobehavioral teratogen that disrupts brain development by preempting the natural, neurotrophic roles
of acetylcholine. Through its actions on nicotinic cholinergic receptors, nicotine elicits abnormalities of neural cell proliferation and differentiation, promotes apoptosis and produces deficits in the number of neural cells and in synaptic function. The effects eventually compromise multiple neurotransmitter systems because of the widespread regulatory role of cholinergic neurotransmission. Importantly, the long-term alterations include effects on reward systems that reinforce the subsequent susceptibility to nicotine addiction in later life. These considerations strongly question the appropriateness of nicotine replacement therapy (NRT) for smoking cessation in pregnant women, especially as the pharmacokinetics of the transdermal patch may actually enhance fetal nicotine exposure. Further, because brain maturation continues into adolescence, the period when smoking typically commences, adolescence is also a vulnerable period in which nicotine can change the trajectory of neurodevelopment. There are also serious questions as to whether NRT is actually effective as an aid to smoking cessation in pregnant women and adolescents. This review considers the ramifications of the basic science findings of nicotine’s effects on brain development for NRT in these populations.


Nicotinic acetylcholine receptors (nAChRs) constitute a heterogeneous family of ion channels that mediate fast synaptic transmission in neurons. They have also been found on non-neuronal cells such as bronchial epithelium and keratinocytes, underscoring the idea that they have functions well beyond neurotransmission. Components of cigarette smoke, including nicotine and NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone], are agonists of nAChRs. Given the association of tobacco use with several diseases, the non-neuronal nAChR signaling pathway has considerable implications for cancer and cardiovascular disease. Recent studies have shown that alpha7 is the main nAChR subunit that mediates the proliferative effects of nicotine in cancer cells. As a result, alpha7 nAChR might be a valuable molecular target for therapy of cancers such as lung cancer and mesothelioma. Future studies involving the design of nAChR antagonists with improved selectivity might identify novel strategies for the treatment of tobacco-related cancers.

Here we review the cellular roles of non-neuronal nAChRs, including regulation of cell proliferation, angiogenesis, apoptosis, migration, invasion and secretion.


Cigarette smoking is associated with a plethora of different diseases. Nicotine is the addictive component of cigarette but also acts onto cells of the non-neuronal system, including immune effector cells. Although nicotine itself is usually not referred to as a carcinogen, there is ongoing debate whether nicotine functions as a ‘tumor enhancer.’ By binding to nicotinic acetylcholine receptors, nicotine deregulates essential biological functions.
processes like angiogenesis, apoptosis, and cell-mediated immunity. Apoptosis plays critical roles in a wide variety of physiologic processes during fetal development and in adult tissue and is also a fundamental aspect of the biology of malignant diseases. This review provides an overview of how nicotine influences apoptotic processes and is thus directly involved in the etiology of pathological conditions like cancer and obstructive diseases.


Prenatal exposure to tobacco smoke is a major risk factor for the newborn, increasing morbidity and even mortality in the neonatal period but also beyond. As nicotine addiction is the factor preventing many women from smoking cessation during pregnancy, nicotine replacement therapy (NRT) has been suggested as a better alternative for the fetus. However, the safety of NRT has not been well documented, and animal studies have in fact pointed to nicotine per se as being responsible for a multitude of these detrimental effects. Nicotine interacts with endogenous acetylcholine receptors in the brain and lung, and exposure during development interferes with normal neurotransmitter function, thus evoking neurodevelopmental abnormalities by disrupting the timing of neurotrophic actions. As exposure to pure nicotine is quite uncommon in pregnant women, very little human data exist aside from the vast literature on prenatal exposure to tobacco smoke. The current review discusses recent findings in humans on effects on the newborn of prenatal exposure to pure nicotine and non-smoke tobacco. It also reviews the neuropharmacological properties of nicotine during gestation and findings in animal experiments that offer explanations on a cellular level for the pathogenesis of such prenatal drug exposure. It is concluded that as findings indicate that functional nAChRs are present very early in neuronal development, and that activation at this stage leads to apoptosis and mitotic abnormalities, a total abstinence from all forms of nicotine should be advised to pregnant women for the entirety of gestation.

Full text here http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656811/

Grozio A, Catassi A, Cavalieri Z, Paleari L, Cesario A, Russo P.
The respiratory epithelium expresses the cholinergic system including nicotinic receptors (nAChRs). It was reported that normal human bronchial epithelial cells (BEC), which are the precursor for squamous cell carcinomas, and small airway epithelial cells (SAEC), which are the precursor for adenocarcinomas, have slightly different repertoires of nAChRs. Studies show that nAChRs expressed on lung carcinoma or mesothelioma form a part of an autocrine-proliferative network facilitating the growth of neoplastic cells; others demonstrated that nicotine can promote the growth of colon, gastric, and lung cancers. Nicotine and structurally related carcinogens like NNK [4-(methylnitrosoamino)-1-(3-
pyridyl]-1-butanone] and NNN (N'-nitrosonornicotine) could induce the proliferation of a variety of small cell lung carcinoma cell lines and endothelial cells and nicotine in non-neuronal tissues -including lung- induces the secretion of growth factors (bFGF, TGF-alpha, VEGF and PDGF), up regulation of the calpain family proteins, COX-2 and VEGFR-2, causing the eventual activation of Raf/MAPK kinase/ERK (Raf/MEK/ERK) pathway contributing to the growth and progression of tumors exposed to nicotine through tobacco smoke or cigarette substitutes. It has been demonstrated that nicotine promotes the growth of solid tumors in vivo, suggesting that might induce the progression of tumors already initiated. While tobacco carcinogens can initiate and promote tumorigenesis, the exposure to nicotine could confer a proliferative advantage to early tumors but there is no evidence that nicotine itself provokes cancer. This is supported by the findings that nicotine can prevent apoptosis induced by various agents - such as chemotherapeutic in NSCLC, conferring a survival advantage as well.

Increasing use of tobacco and its related health problems are a great concern in the world. Recent epidemiological findings have demonstrated the positive association between cigarette smoking and several gastrointestinal (GI) diseases, including peptic ulcer and cancers. Interestingly, smoking also modifies the disease course of ulcerative colitis (UC). Nicotine, a major component of cigarette smoke, seems to mediate some of the actions of cigarette smoking on the pathogenesis of GI disorders. Nicotine worsens the detrimental effects of aggressive factors and attenuates the protective actions of defensive factors in the processes of development and repair of gastric ulceration. Nicotine also takes part in the initiation and promotion of carcinogenesis in the GI tract. In this regard, nicotine and its metabolites are found to be mutagenic and have the ability to modulate cell proliferation, apoptosis, and angiogenesis during tumoriogenesis through specific receptors and signalling pathways. However, to elucidate this complex pathogenic mechanism, further study at the molecular level is warranted. In contrast, findings of clinical trials give promising results on the use of nicotine as an adjuvant therapy for UC. The beneficial effect of nicotine on UC seems to be mediated through multiple mechanisms. More clinical studies are needed to establish the therapeutic value of nicotine in this disease.


http://ac.els-cdn.com/S1535610803002198/1-s2.0-S1535610803002198-main.pdf?_tid=ad1f8084-a439-11e5-b823-00000aab0f6c&acdnat=1450300512_9ba5bb948ad346910e374692a9b5715a (full text)
Exposure to second hand smoke (SHS) is believed to cause lung cancer. Pathological angiogenesis is a requisite for tumor growth. Lewis lung cancer cells were injected subcutaneously into mice, which were then exposed to sidestream smoke (SHS) or clean room air and administered vehicle, cerivastatin, or mecamylamine. 

**SHS significantly increased tumor size, weight, capillary density, VEGF and MCP-1 levels, and circulating endothelial progenitor cells (EPC).** Cerivastatin (an inhibitor of HMG-coA reductase) or mecamylamine (an inhibitor of nicotinic acetylcholine receptors) suppressed the effect of SHS to increase tumor size and capillary density. Cerivastatin reduced MCP-1 levels, whereas mecamylamine reduced VEGF levels and EPC. **These studies reveal that SHS promotes tumor angiogenesis and growth. These effects of SHS are associated with increases in plasma VEGF and MCP-1 levels, and EPC, mediated in part by isoprenylation and nicotinic acetylcholine receptors.**

And also:


The elimination of cigarettes and other combusted tobacco products in the U.S. would prevent tens of millions of tobacco-related deaths. It has been suggested that the introduction of less harmful nicotine delivery devices, such as electronic cigarettes or other electronic nicotine delivery systems, will accelerate progress toward ending combustible cigarette use. However, **careful consideration of the potential adverse health effects from nicotine itself is often absent from public health debates. Human and animal data support that nicotine exposure during periods of developmental vulnerability (fetal through adolescent stages) has multiple adverse health consequences, including impaired fetal brain and lung development, and altered development of cerebral cortex and hippocampus in adolescents.** Measures to protect the health of pregnant women and children are needed and could include (1) strong prohibitions on marketing that increase youth uptake; (2) youth access laws similar to those in effect for other tobacco products; (3) appropriate health warnings for vulnerable populations; (4) packaging to prevent accidental poisonings; (5) protection of non-users from exposure to secondhand electronic cigarette aerosol; (6) pricing that helps minimize youth initiation and use; (7) regulations to reduce product addiction potential and appeal for youth; and (8) the age of legal sale.
References


Alpert H et al. A study of pyrazines in cigarettes and how additives might be used to enhance tobacco addiction. Tob Control 2015;0:1–7. doi:10.1136/tobaccocontrol-2014-051943


Beard E et al. Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4645 (Published 13 September 2016)


Doran N et al. Does e-cigarette use predict cigarette escalation? A longitudinal study of


Fröhlich E. Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological Screening. Drug Delivery, 2017 24:1, 891-905,


Goniewicz M et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tobacco Control Published Online First: 06 March 2013. DOI: 10.1136/tobaccocontrol-2012-050859


Knight J, Chapman S. "A phony way to show sincerity, as we all well know": tobacco industry lobbying against tobacco control in Hong Kong. Tobacco Control 2004; 13 (Suppl 2): ii13-21.


Khlystov A and Samburova V. "Flavoring compounds dominate toxic aldehyde production during e-cigarette vaping." *Environmental science & technology* 50.23 (2016): 13080-13085.


Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. *Respir Care* 2005 Sep;50(9):1201-8.


Temesgen et al. A cross sectional study reveals an association between electronic cigarette use and myocardial infarction. Available at: http://hsrce.himmelfarb.gwu.edu/gw_research_days/2017/SMHS/85/. Please note: for a full discussion if the Temegesen et al peer reviewed presentation of data, please visit: https://tobacco.ucsf.edu/first-evidence-e-cig-use-increases-heart-attacks-independent-effect-smoking-cigarettes


